Centers for Disease Control and Prevention
MMWR
Morbidity and Mortality Weekly Report
Weekly / Vol. 68 / No. 39
October 4, 2019

National Trends in Hepatitis C Infection by Opioid Use Disorder Status Among Pregnant Women at Delivery Hospitalization — United States, 2000–2015

Jean Y. Ko, PhD[1]; Sarah C. Haight, MPH[1]; Sarah F. Schillie, MD[2]; Michele K. Bohm, MPH[3]; Patricia M. Dietz, DrPH[2]

Hepatitis C virus (HCV) is transmitted primarily through parenteral exposures to infectious blood or body fluids that contain blood (e.g., via injection drug use, needle stick injuries) (*1*). In the last 10 years, increases in HCV infection in the general U.S. population (*1*) and among pregnant women (*2*) are attributed to a surge in injection drug use associated with the opioid crisis. Opioid use disorders among pregnant women have increased (*3*), and approximately 68% of pregnant women with HCV infection have opioid use disorder (*4*). National trends in HCV infection among pregnant women by opioid use disorder status have not been reported to date. CDC analyzed hospital discharge data from the 2000–2015 Healthcare Cost and Utilization Project (HCUP) to determine whether HCV infection trends differ by opioid use disorder status at delivery. During this period, the national rate of HCV infection among women giving birth increased >400%, from 0.8 to 4.1 per 1,000 deliveries. Among women with opioid use disorder, rates of HCV infection increased 148%, from 87.4 to 216.9 per 1,000 deliveries, and among those without opioid use disorder, rates increased 271%, although the rates in this group were much lower, increasing from 0.7 to 2.6 per 1,000 deliveries. These findings align with prior ecological data linking hepatitis C increases with the opioid crisis (*2*). Treatment of opioid use disorder should include screening and referral for related conditions such as HCV infection.

To evaluate HCV infection prevalence at hospital delivery among women with and without opioid use disorder, data from HCUP's National Inpatient Sample (NIS, 2000–2015) (https://www.hcup-us.ahrq.gov/) were analyzed. The fourth quarter of 2015 and more recent data were excluded because of the transition to the *International Classification of Diseases, Tenth Revision, Clinical Modification* (ICD-10-CM) during that period. The NIS is the largest publicly available all-payer inpatient health care database in the United States, yielding national estimates representing approximately 35 million hospitalizations. Discharges for in-hospital deliveries were identified using *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD-9-CM) diagnostic and procedure codes pertaining to obstetric delivery (*5*).

HCV infection was identified from ICD-9-CM codes 070.41, 070.44, 070.51, 070.54, 070.70, 070.71, and V02.62;

INSIDE

Continuing Education examination available at https://www.cdc.gov/mmwr/cme/conted_info.html#weekly.

U.S. Department of Health and Human Services
Centers for Disease Control and Prevention

and opioid use disorder was identified from codes for opioid dependence and nondependent abuse (304.00–304.03, 304.70–304.73, and 305.50–305.53), aligning with *Diagnostic and Statistical Manual of Mental Disorders, 5th Edition* criteria* (*6*). Deliveries were categorized by maternal diagnoses: HCV infection only, opioid use disorder only, both HCV infection and opioid use disorder, or neither. Demographic variables of interest included age, payer source, race/ethnicity, median income quartiles for residency ZIP code, and hospital geographic region.

Survey-specific analysis techniques accounted for clustering, stratification, and weighting. National annual prevalence rates of opioid use disorder and HCV infection per 1,000 delivery hospitalizations during 2000–2015 and 95% confidence intervals (CIs) were calculated using SAS (version 9.4; SAS Institute). HCV infection rates were calculated by opioid use disorder status. Joinpoint regression was used to model the average percentage change in HCV infection and opioid use disorder rates over time and their statistical significance. The program identifies points (joinpoints) where the slope of the trend significantly changes and calculates the average percentage change in the rate during the years between joinpoints. Using 2015 data, distribution of diagnoses by payer source, race/ethnicity, median income for residency ZIP code, and hospital region were calculated. Polytomous logistic regression models were used to calculate unadjusted odds ratios (ORs) and 95% CIs comparing the likelihood of each delivery hospitalization having one or both diagnoses versus neither by sociodemographic characteristics. Statistical significance was set at $p<0.05$.

During 2000–2015, the rate of HCV infection increased from 0.8 (95% CI = 0.7–0.9) to 4.1 (95% CI = 3.7–4.4) per 1,000 deliveries. Rates significantly increased from 2000 to 2004 (15.7%; $p<0.001$), 2004 to 2010 (6.1%; $p<0.001$), and 2010 to 2015 (14.9%; $p<0.001$). Among deliveries with opioid use disorder diagnoses, the rate of maternal HCV infection increased from 87.4 (95% CI = 56.3–118.5) to 216.9 (95% CI = 197.9–235.9) per 1,000 deliveries (Figure). The rate significantly increased during 2000–2004 (17.2%; $p<0.001$), remained statistically unchanged during 2004–2011 (-2.4%; $p = 0.1$), and significantly increased during 2011–2015 (7.9%; $p<0.001$). Among deliveries without opioid use disorder diagnoses, the rate of HCV infection increased from 0.7 (95% CI = 0.6–0.8) to 2.6 (95% CI = 2.4–2.9) per 1,000 deliveries during 2000–2015. The rate remained statistically unchanged during 2000–2002 (21.1%; $p = 0.1$), and significantly increased during 2002–2011 (5.5%; $p<0.001$) and 2011–2015 (15.0%; $p<0.001$).

In 2015, all three groups (those with HCV infection only, opioid use disorder only, and both HCV infection and opioid

* ICD-9-CM codes related to opioid dependence and nondependent abuse, in remission, were included in this analysis because both early remission and opioid use disorder could have occurred during pregnancy.

The *MMWR* series of publications is published by the Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30329-4027.

Suggested citation: [Author names; first three, then et al., if more than six.] [Report title]. MMWR Morb Mortal Wkly Rep 2019;68:[inclusive page numbers].

FIGURE. National prevalence* of maternal hepatitis C virus (HCV) infection per 1,000 delivery hospitalizations, by opioid use disorder (OUD) status, 2000–2015†



* Prevalence numerator consisted of HCV infection *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD-9-CM) codes (070.41, 070.44, 070.51, 070.54, 070.70, 070.71, and V02.62), and denominator consisted of delivery hospitalizations discharges with and without opioid type dependence and nondependent opioid abuse based on ICD-9-CM codes (304.00–304.03, 304.70–304.73, and 305.50–305.53).
† Rates are for 2000 through the third quarter of 2015.

use disorder) shared similar risk factors (Table 1). Compared with women aged ≥35 years, those aged 25–34 years were more likely to have a diagnosis of HCV infection (OR = 1.2, 95% CI = 1.0–1.4), opioid use disorder (OR = 1.8, 95% CI = 1.6–2.0), or both (OR = 1.8, 95% CI: 1.4–2.3) at delivery (Table 2). Women with publicly billed deliveries (Medicaid or Medicare) were the most likely to have a diagnosis of HCV infection (OR = 5.5, 95% CI = 4.7–6.4), opioid use disorder (OR = 6.4, 95% CI = 5.8–7.2), or both (OR = 9.9, 95% CI = 7.8–12.6) at delivery, compared with privately billed deliveries. Compared with non-Hispanic black women, Native American women were the most likely to have a diagnosis of HCV infection (OR = 5.0, 95% CI = 2.9–8.7) or opioid use disorder (OR = 5.9, 95% CI = 4.0–8.8) at delivery, and non-Hispanic white women were the most likely to have a diagnosis of both (OR = 10.9, 95% CI = 6.3–18.6) at delivery. Women from areas with median income of <$42,000 were the most likely to receive a diagnosis of HCV infection (OR = 2.5, 95% CI = 2.0–3.0), opioid use disorder (OR = 2.0, 95% CI = 1.7–2.3), or both (OR = 2.5, 95% CI = 1.8–3.4) at delivery, compared with those from areas with median income ≥$68,000. Compared with U.S. residents of the Western census region (the referent group), residents of the South were the most likely to receive a diagnosis of HCV infection (OR = 1.9, 95% CI = 1.5–2.3) at delivery. Women living in the Northeast were the most likely to receive a diagnosis of opioid use disorder (OR = 2.0, 95% CI = 1.6–2.4) or both HCV infection and opioid use disorder (OR = 4.8, 95% CI = 3.1–7.5) at delivery.

Discussion

In the United States, the 2015 rate of HCV infection at delivery hospitalization (4.1 per 1,000) was approximately five times higher than it was in 2000 (0.8 per 1,000). Rates were substantially higher among women with opioid use disorder, suggesting a link between the opioid crisis and increases in HCV infection. Results from this analysis are consistent with previously reported findings. For example, these estimates using hospital discharge data are similar to those from an analysis of birth certificate data, which found that maternal HCV infection almost doubled during 2009–2014 from 1.8 to 3.4 per 1,000 live births (*2*). Increased likelihood of HCV infection, opioid use disorder diagnosis, or both among women with publicly billed deliveries is similar to previous findings that women with HCV infection were more likely to be Medicaid-insured (*4*). In this analysis, Native American women were significantly more likely to have an HCV infection or opioid use disorder diagnosis at delivery than were non-Hispanic black women. High rates of overdose deaths and HCV infection in American Indian and Alaska Native persons have been previously noted in the general adult population (*7*,*8*). Lower HCV infection rates at delivery among women in the West reflect distribution of HCV infection in the general population (*1*).

Current U.S. Preventive Service Task Force and CDC guidelines recommend hepatitis C testing for persons at high risk (e.g., persons who inject drugs[†,§]); however, epidemiologic

† https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/hepatitis-c-screening.
§ https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm.

TABLE 1. Prevalence of hepatitis C virus (HCV) infection and opioid use disorder* at delivery hospitalization, by demographic characteristic (N = 2,860,130) — United States, 2015†

Characteristic	Total§	HCV infection only		Opioid use disorder only		HCV infection and opioid use disorder	
	No. (95% CI)	No. (95% CI)	Prevalence % (95% CI)	No. (95% CI)	Prevalence % (95% CI)	No. (95% CI)	Prevalence % (95% CI)
Age group (yrs)							
<25	784,830 (759,112–810,548)	1,820 (1,563–2,077)	0.2 (0.2–0.3)	4,000 (3,640–4,360)	0.5 (0.5–0.6)	1,005 (821–1,189)	0.1 (0.1–0.2)
25–34	1,616,900 (1,560,018–1,673,782)	4,560 (4,161–4,959)	0.3 (0.3–0.3)	9,380 (8,686–10,074)	0.6 (0.5–0.6)	2,695 (2,313–3,077)	0.2 (0.1–0.2)
≥35	458,380 (437,269–479,491)	1,115 (962–1,268)	0.2 (0.2–0.3)	1,495 (1,310–1,680)	0.3 (0.3–0.4)	420 (322–518)	0.1 (0.1–0.1)
Payer source							
Public¶	1,240,210 (1,193,733–1,286,686)	5,885 (5,344–6,426)	0.5 (0.4–0.5)	12,025 (11,147–12,903)	1.0 (0.9–1.0)	3,565 (3,067–4,063)	0.3 (0.2–0.3)
Private**	1,466,650 (1,401,828–1,531,472)	1,290 (1,115–1,465)	0.1 (0.1–0.1)	2,245 (1,999–2,491)	0.2 (0.1–0.2)	430 (327–533)	0.0 (0.0–0.0)
Other/Self pay††	148,680 (138,378–158,982)	310 (231–389)	0.2 (0.2–0.3)	575 (463–687)	0.4 (0.3–0.5)	115 (64–166)	0.1 (0.0–0.1)
Race/Ethnicity§§							
White	1,418,351 (1,362,897–1,473,804)	5,705 (5,158–6,252)	0.4 (0.4–0.4)	11,565 (10,700–12,430)	0.8 (0.8–0.9)	3,470 (2,985–3,955)	0.2 (0.2–0.3)
Black	395,535 (371,201–419,868)	450 (351–549)	0.1 (0.1–0.1)	885 (726–1,044)	0.2 (0.2–0.3)	90 (40–140)	0.0 (0.0–0.0)
Hispanic	552,715 (516,126–589,304)	470 (375–565)	0.1 (0.1–0.1)	925 (757–1,093)	0.2 (0.1–0.2)	220 (115–325)	0.0 (0.0–0.1)
Native American	19,555 (16,288–22,822)	110 (47–173)	0.6 (0.3–0.8)	255 (157–353)	1.3 (0.8–1.8)	35 (0–70)	0.2 (0.0–0.3)
Asian-Pacific Islander/Other	274,615 (252,818–296,412)	300 (206–394)	0.1 (0.1–0.1)	350 (250–450)	0.1 (0.1–0.2)	65 (1–129)	0.0 (0.0–0.0)
Median income for ZIP code¶¶ ($)							
1–41,999	822,850 (783,465–862,234)	2,935 (2,552–3,318)	0.4 (0.3–0.4)	5,225 (4,697–5,753)	0.6 (0.6–0.7)	1,630 (1,352–1,908)	0.2 (0.2–0.2)
42,000–51,999	671,335 (643,392–699,278)	2,010 (1,780–2,240)	0.3 (0.3–0.3)	3,925 (3,538–4,312)	0.6 (0.5–0.6)	1,045 (845–1,245)	0.2 (0.1–0.2)
52,000–67,999	700,610 (669,764–731,456)	1,420 (1,229–1,611)	0.2 (0.2–0.2)	3,395 (3,043–3,747)	0.5 (0.4–0.5)	840 (686–994)	0.1 (0.1–0.1)
≥68,000	628,510 (581,576–675,444)	920 (770–1,070)	0.1 (0.1–0.2)	2,050 (1,766–2,334)	0.3 (0.3–0.4)	505 (370–640)	0.1 (0.1–0.1)
Region***							
Northeast	457,160 (418,652–495,668)	1,110 (927–1,293)	0.2 (0.2–0.3)	3,390 (2,902–3,878)	0.7 (0.6–0.8)	1,190 900–1,480)	0.3 (0.2–0.3)
Midwest	608,746 (570,546–646,947)	1,375 (1,152–1,598)	0.2 (0.2–0.3)	3,300 (2,849–3,751)	0.5 (0.5–0.6)	895 (630–1,160)	0.1 (0.1–0.2)
South	1,111,188 (1,046,643–1,175,733)	3,760 (3,265–4,255)	0.3 (0.3–0.4)	5,600 (4,941–6,259)	0.5 (0.4–0.6)	1,665 (1,313–2,017)	0.1 (0.1–0.2)
West	683,036 (637,875–728,198	1,250 (1,063–1,437)	0.2 (0.2–0.2)	2,585 (2,199–2,971)	0.4 (0.3–0.4)	370 (232–508)	0.1 (0.0–0.1)

Abbreviation: CI = confidence interval.

* Includes *International Classification of Diseases, Ninth Revision, Clinical Modification* codes for HCV infection (070.41, 070.44, 070.51, 070.54, 070.70–070.71, and V02.62) and opioid use disorder (304.00–304.03, 304.70–304.73, and 305.50–305.53).

† Only representative of the first three quarters of 2015.

§ Includes deliveries with HCV infection only, opioid use disorder only, HCV infection and opioid use disorder, and neither HCV or opioid use disorder diagnoses.

¶ Includes Medicare and Medicaid.

** Includes Blue Cross, commercial carriers, private health maintenance organizations, and preferred provider organizations.

†† Includes worker's compensation, Civilian Health and Medical Program of the Uniformed Services, Civilian Health and Medical Program of the Department of Veteran's Affairs, Title V, and other government programs.

§§ Whites, blacks, Native Americans, and Asian-Pacific Islanders/Others were non-Hispanic; Hispanic persons could be of any race.

¶¶ Estimated median household income of residents in the patient's ZIP code derived from ZIP code demographic data obtained from Claritas (https://www.hcup-us.ahrq.gov/db/vars/zipinc_qrtl/nisnote.jsp).

*** *Northeast*: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont. *Midwest*: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin. *South*: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia. *West*: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.

TABLE 2. Association of hepatitis C virus (HCV) infection and opioid use disorder* at delivery hospitalization with demographic characteristics (N = 2,860,130) — United States, 2015†

Characteristic	OR (95% CI)		
	HCV infection only	Opioid use disorder only	HCV infection and opioid use disorder
Age group (yrs)			
<25	1.0 (0.8–1.1)	1.6 (1.4–1.8)§	1.4 (1.1–1.8)§
25–34	1.2 (1.0–1.4)§	1.8 (1.6–2.0)§	1.8 (1.4–2.3)§
≥35	Ref.	Ref.	Ref.
Payer source			
Public¶	5.5 (4.7–6.4)§	6.4 (5.8–7.2)§	9.9 (7.8–12.6)§
Private**	Ref.	Ref.	Ref.
Other/Self pay††	2.4 (1.8–3.2)§	2.5 (2.0–3.1)§	2.6 (1.6–4.3)§
Race/Ethnicity§§			
White	3.6 (2.9–4.5)§	3.7 (3.1–4.4)§	10.9 (6.3–18.6)§
Black	Ref.	Ref.	Ref.
Hispanic	0.7 (0.6–1.0)	0.7 (0.6–1.0)	1.7 (0.8–3.6)
Native American	5.0 (2.9–8.7)§	5.9 (4.0–8.8)§	8.0 (2.7–23.5)§
Asian-Pacific Islander/Other	1.0 (0.7–1.4)	0.6 (0.4–0.8)§	1.0 (0.4–2.9)
Median income for ZIP code¶¶ ($)			
1–41,999	2.5 (2.0–3.0)§	2.0 (1.7–2.3)§	2.5 (1.8–3.4)§
42,000–51,999	2.1 (1.7–2.5)§	1.8 (1.5–2.1)§	1.9 (1.5–2.6)§
52,000–67,999	1.4 (1.1–1.7)§	1.5 (1.3–1.7)§	1.5 (1.1–2.0)§
≥68,000	Ref.	Ref.	Ref.
Region***			
Northeast	1.3 (1.1–1.7)§	2.0 (1.6–2.4)§	4.8 (3.1–7.5)§
Midwest	1.2 (1.0–1.5)	1.4 (1.2–1.8)§	2.7 (1.7–4.4)§
South	1.9 (1.5–2.3)§	1.3 (1.1–1.6)§	2.8 (1.8–4.3)§
West	Ref.	Ref.	Ref.

Abbreviations: CI = confidence interval; Ref. = referent; OR = odds ratio.

* Includes *International Classification of Diseases, Ninth Revision, Clinical Modification* codes for HCV infection (070.41, 070.44, 070.51, 070.54, 070.70–070.71, and V02.62) and opioid use disorder (304.00–304.03, 304.70–304.73, and 305.50–305.53).

† Only representative of the first three quarters of 2015.

§ p<0.05.

¶ Includes Medicare and Medicaid.

** Includes Blue Cross, commercial carriers, private health maintenance organizations, and preferred provider organizations.

†† Includes worker's compensation, Civilian Health and Medical Program of the Uniformed Services, Civilian Health and Medical Program of the Department of Veteran's Affairs, Title V, and other government programs.

§§ Whites, blacks, Native Americans, and Asian-Pacific Islanders/Others were non-Hispanic; Hispanic persons could be of any race.

¶¶ Estimated median household income of residents in the patient's ZIP code derived from ZIP code demographic data obtained from Claritas (https://www.hcup-us.ahrq.gov/db/vars/zipinc_qrtl/nisnote.jsp).

*** *Northeast*: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont. *Midwest*: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin. *South*: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia. *West*: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.

changes in HCV infection in the United States have prompted a review of the evidence informing HCV testing by the U.S. Preventive Services Task Force and CDC. The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America recommend hepatitis C screening for all pregnant women (*9*). Hepatitis C treatment for adults with direct-acting antiviral agents consists of an oral regimen of ≤12 weeks, resulting in a virologic cure in >90% of infected persons (*10*). Although treatment of HCV infection with direct-acting antiviral agents during pregnancy is not approved (*10*), testing remains important to identify infections, engage infected women in postpartum treatment, and identify infants who might have been exposed. Left untreated, HCV infection might lead to cirrhosis and pose continued risk to others through parenteral exposures (e.g., injection drug use or transmission via subsequent pregnancies) (*1*).

The findings in this report are subject to at least five limitations. First, this study likely produced underestimates of opioid use disorder and HCV infection. Although universal screening for substance use is the standard of care during pregnancy, it is not universally implemented. Further, stigma and associated fear of reporting opioid use disorder likely reduces self-disclosure. Risk-based hepatitis C testing is the current care standard but might not be adequately implemented. Second, increases in observed rates might reflect changes in screening practices and protocols for opioid use disorder and HCV in addition to actual increases in these conditions. Third, ICD-9-CM does not differentiate between chronic or incident

Summary

What is already known about this topic?

Ecological studies link increases in hepatitis C virus (HCV) infection to the U.S. opioid crisis. Opioid use disorder among pregnant women has increased; the majority of those with HCV infection have opioid use disorder.

What is added by this report?

The U.S. rate of HCV infection at delivery increased from 0.8 per 1,000 live births in 2000 to 4.1 in 2015, including increases from 87.4 to 216.9 and from 0.7 to 2.6 among women with and without opioid use disorder, respectively.

What are the implications for public health practice?

Treatment of opioid use disorder should include screening and referral for related conditions such as HCV infection.

acute HCV infection. Fourth, these analyses might not represent most recent trends because data were only analyzed up to the third quarter of 2015. Finally, results of this analysis are only generalizable to hospital births; however, fewer than 2% of U.S births occur outside of the hospital.¶

Opioid use disorder (*3*) and HCV infection rates significantly increased during 2000–2015 among women delivering in hospitals in the United States. HCV infection rates at delivery were significantly higher among women with opioid use disorder than among those who did not have opioid use disorder. Treatment of opioid use disorder should include screening and referral for related conditions such as HCV infection.

¶ https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_01.pdf.

Acknowledgments

Katelyn Chiang, MPH; Agency for Healthcare Research and Quality, Healthcare Cost and Utilization Project and its data partners that contribute to the National Inpatient Sample.

Corresponding author: Jean Y. Ko, JeanKo@cdc.gov, 770-488-5200.

[1]Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, CDC; [2]National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC; [3]Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, CDC.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

References

1. CDC. Surveillance for viral hepatitis—United States, 2016. Atlanta, GA: US Department of Health and Human Services, CDC; 2018. https://www.cdc.gov/hepatitis/statistics/2016surveillance/commentary.htm
2. Patrick SW, Bauer AM, Warren MD, Jones TF, Wester C. Hepatitis C virus infection among women giving birth—Tennessee and United States, 2009–2014. MMWR Morb Mortal Wkly Rep 2017;66:470–3. https://doi.org/10.15585/mmwr.mm6618a3
3. Haight SC, Ko JY, Tong VT, Bohm MK, Callaghan WM. Opioid use disorder documented at delivery hospitalization—United States, 1999–2014. MMWR Morb Mortal Wkly Rep 2018;67:845–9. https://doi.org/10.15585/mmwr.mm6731a1
4. Chappell CA, Hillier SL, Crowe D, Meyn LA, Bogen DL, Krans EE. Hepatitis C virus screening among children exposed during pregnancy. Pediatrics 2018;141:e20173273. https://doi.org/10.1542/peds.2017-3273
5. Kuklina EV, Whiteman MK, Hillis SD, et al. An enhanced method for identifying obstetric deliveries: implications for estimating maternal morbidity. Matern Child Health J 2008;12:469–77. https://doi.org/10.1007/s10995-007-0256-6
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Association; 2013.
7. Rempel JD, Uhanova J. Hepatitis C virus in American Indian/Alaskan Native and aboriginal peoples of North America. Viruses 2012;4:3912–31. https://doi.org/10.3390/v4123912
8. Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. MMWR Morb Mortal Wkly Rep 2018;67:349–58. https://doi.org/10.15585/mmwr.mm6712a1
9. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV in pregnancy. Alexandra, VA: American Association for the Study of Liver Diseases; Arlington, VA: Infectious Diseases Society of America; 2018. https://www.hcvguidelines.org/unique-populations/pregnancy
10. Hughes BL, Page CM, Kuller JA; Society for Maternal-Fetal Medicine. Hepatitis C in pregnancy: screening, treatment, and management. Am J Obstet Gynecol 2017;217:B2–12. https://doi.org/10.1016/j.ajog.2017.07.039

Flavored Tobacco Product Use Among Middle and High School Students — United States, 2014–2018

Karen A. Cullen, PhD[1]; Sherry T. Liu, PhD[1]; Jennifer K. Bernat, PhD[1]; Wendy I. Slavit, MPH[1]; Michael A. Tynan[2]; Brian A. King, PhD[2]; Linda J. Neff, PhD[2]

The 2009 Family Smoking Prevention and Tobacco Control Act prohibits the inclusion of characterizing flavors (e.g., candy or fruit) other than tobacco and menthol in cigarettes; however, characterizing flavors are not currently prohibited in other tobacco products at the federal level.* Flavored tobacco products can appeal to youths and young adults and influence initiation and establishment of tobacco-use patterns (*1*). The Food and Drug Administration (FDA) and CDC analyzed data from the 2014–2018 National Youth Tobacco Surveys (NYTS) to determine prevalence of current (past 30-day) use of flavored tobacco products, including electronic cigarettes (e-cigarettes), hookah tobacco, cigars, pipe tobacco, smokeless tobacco, bidis, and menthol cigarettes among U.S. middle school (grades 6–8) and high school (grades 9–12) students. In 2018, an estimated 3.15 million (64.1%) youth tobacco product users currently used one or more flavored tobacco products, compared with 3.26 million (70.0%) in 2014. Despite this overall decrease in use of flavored tobacco products, current use of flavored e-cigarettes increased among high school students during 2014–2018; among middle school students, current use of flavored e-cigarettes increased during 2015–2018, following a decrease during 2014–2015. During 2014–2018, current use of flavored hookah tobacco decreased among middle and high school students; current use of flavored smokeless tobacco, cigars, pipe tobacco, and menthol cigarettes decreased among high school students. Full implementation of comprehensive tobacco prevention and control strategies, coupled with regulation of tobacco products by FDA, can help prevent and reduce use of tobacco products, including flavored tobacco products, among U.S. youths (*2*,*3*).

NYTS is an annual cross-sectional, school-based, self-administered, pencil-and-paper questionnaire administered to U.S. middle and high school students.† A three-stage cluster sampling procedure was used to generate a nationally representative sample of U.S. students attending public or private schools in grades 6–12. This report uses data from five NYTS waves (2014–2018). Sample sizes and response rates were 22,007 (73.3%) in 2014; 17,711 (63.4%) in 2015; 20,675 (71.6%) in 2016; 17,872 (68.1%) in 2017; and 20,189 (68.2%) in 2018.

Participants were asked about current (≥1 day during the past 30 days) use of cigarettes, e-cigarettes, hookahs, cigars, pipe tobacco, smokeless tobacco, snus, dissolvable tobacco products, and bidis. Current cigarette smoking was determined by asking "During the past 30 days, on how many days did you smoke cigarettes?" Current use of cigars was determined by asking "During the past 30 days, on how many days did you smoke cigars, cigarillos, or little cigars?" Current use of smokeless tobacco was determined by asking "During the past 30 days, on how many days did you use chewing tobacco, snuff, or dip?" Current use of e-cigarettes was determined by asking "During the last 30 days, on how many days did you use e-cigarettes?" Current use of hookahs was determined by asking "During the past 30 days, on how many days did you smoke tobacco in a hookah or waterpipe?" Current use of pipe tobacco (not hookahs), snus, dissolvable tobacco, and bidis were determined by asking "In the past 30 days, which of the following products have you used on at least one day?" "Any tobacco" use was defined as current use of one or more tobacco products. "Any smokeless tobacco" use was defined as current use of smokeless tobacco (chewing tobacco, snuff, or dip), snus, or dissolvables. Participants were also asked about any current use of tobacco products that were "flavored to taste like menthol (mint), alcohol (wine, cognac), candy, fruit, chocolate, or any other flavors." Participants could select from a list of flavored tobacco products, including each noncigarette tobacco product type. Among students who reported current use of each product, those who selected the flavored product were categorized as flavored tobacco product users. Among current cigarette smokers, menthol smokers were categorized as those who reported "Yes" to the question "During the past 30 days, were the cigarettes that you usually smoked menthol," or who reported "Newport" or "Kool" as the usual cigarette brand because these brands produce menthol cigarettes exclusively or predominantly.

Data were weighted to account for the complex survey design and adjusted for nonresponse; national prevalence estimates were calculated with 95% confidence intervals.

* Family Smoking Prevention and Tobacco Control Act [Pub. L. No. 111–31, H.R. 1256 (2009)]. https://www.govinfo.gov/content/pkg/PLAW-111publ31/html/PLAW-111publ31.htm.

† https://www.cdc.gov/tobacco/data_statistics/surveys/nyts/index.htm.

Current flavored product use estimates for 2018 were assessed for any tobacco product and for each product individually, by school type, sex, and race/ethnicity. Use of flavored bidis was first included in the survey in 2016, so 2014–2015 data do not include bidis. For each school type, presence of linear and nonlinear (i.e., quadratic) trends were assessed during 2014–2018.[§] For all analyses, p-values <0.05 were considered statistically significant. Analyses were conducted using SAS (version 9.4; SAS Institute) and SUDAAN (version 11.0.3; RTI International).

In 2018, 27.1% of high school students and 7.2% of middle school students reported current use of any tobacco product, corresponding to an estimated 4.92 million middle and high school students who use at least one tobacco product. Among current users of any tobacco product, 64.1% reported using at least one flavored tobacco product in the past 30 days. The percentage of current tobacco users who reported flavored product use in the past 30 days was 65.2% for e-cigarettes, 45.7% for menthol cigarettes, 43.6% for cigars, 38.9% for bidis, 37.5% for any smokeless tobacco, 26.5% for tobacco in pipes, and 26.1% for hookah (Table).

Among high school tobacco product users, a significant nonlinear decrease occurred during 2014–2018 in use of any flavored tobacco product (from 73.0% to 67.4%) (Figure). By product, a significant nonlinear increase in use of flavored e-cigarettes (from 65.1% to 67.8%) occurred; a significant nonlinear decrease in use of flavored smokeless tobacco (from 64.7% to 40.1%) occurred. Significant linear decreases in use of menthol cigarettes (from 54.5% to 46.1%), flavored hookah tobacco (from 63.8% to 27.9%), flavored cigars (from 64.7% to 44.5%), and flavored pipe tobacco (from 44.0% to 27.3%) occurred. Among middle school tobacco product users (Figure), a significant linear decrease in flavored hookah tobacco use (from 44.3% to 18.3%) occurred during 2014–2018. The use of flavored e-cigarettes decreased from 55.1% to 39.2% during 2014–2015 and then increased during 2015–2018 to 51.5%, comparable with the 2014 estimate. No significant change in use of any flavored tobacco, flavored smokeless tobacco, cigars, pipe tobacco, or menthol cigarettes among middle school students occurred during 2014–2018.

Discussion

Nearly two thirds (3.15 million, 64.1%) of middle and high school student current tobacco product users reported current flavored tobacco product use in 2018. E-cigarettes were the most commonly used flavored tobacco product in 2018; flavored e-cigarette use has increased in recent years. During 2014–2018, use of any flavored tobacco product decreased among high school students who currently use tobacco products; however, no change occurred among middle school student users. The high prevalence of flavored tobacco product use among middle and high school students is a concern because flavors can increase the appeal of tobacco products to youths, promote youth initiation of tobacco products, and result in lifelong tobacco product use (*3*,*4*).

A recent examination of online tobacco retailers found that a sizable proportion of noncigarette tobacco products for sale in the United States are flavored (*5*). The recent increase in flavored e-cigarette use among youths might be due, in part, to the recent popularity and increased market share of e-cigarettes shaped like a USB flash drive, such as JUUL; these products can be used discreetly, have a higher nicotine content than earlier generation e-cigarettes, and are available in flavors that appeal to youths (*6*). These attributes might play a role in sustained use; research shows the majority of youths and young adults who reported ever using JUUL also reported being current JUUL users (*7*). Decreases in use of specific flavored tobacco products during the study period might be due to multiple factors, including actual decreases in flavored tobacco product use, a decrease in awareness that the product being used was flavored, or an increase in use of other products in hookahs (e.g., marijuana, herbal [nontobacco] products, or hashish) even though the survey question specifically refers to tobacco use in a hookah or waterpipe.

Population-based strategies at the state and local levels could help reduce use of flavored tobacco products by youths. In recent years, several communities have restricted the sale of flavored tobacco products. In 2009, New York City prohibited the sale of flavored cigars and smokeless tobacco products (excluding flavors such as menthol, mint, and wintergreen) except in adult-only tobacco bars[¶]. This law resulted in a significant decrease in cigar sales, compared with a 12% increase nationally during the same period (*8*). Providence, Rhode Island, passed a similar ordinance in 2012 prohibiting flavored tobacco product sales, including flavored e-cigarettes.[**] More recently, ordinances have also been adopted in Minneapolis, Minnesota; Oakland, California; San Francisco, California; Santa Clara County, California; St. Paul, Minnesota; and

[§] A test for linear trend is significant if an overall statistically significant decrease or increase occurs during the study period. Data were also assessed for the presence of nonlinear (i.e., quadratic) trends; a significant nonlinear (i.e., quadratic) trend indicates that the rate of change accelerated or decelerated across the study period.

[¶] https://www.lawserver.com/law/state/new-york/ny-laws/ny_new_york_city_administrative_code_17-715.

[**] https://www.publichealthlawcenter.org/sites/default/files/resources/US-Sales-Restrictions-Flavored-Tobacco-Products-2017.pdf.

TABLE. Percentage of middle and high school students currently using tobacco products* who reported using flavored products† during the preceding 30 days, by sex and race/ethnicity — National Youth Tobacco Survey, United States, 2018

Characteristic	Tobacco product % (95% CI)							
	Any tobacco§	E-cigarettes	Menthol cigarettes	Cigars	Any smokeless tobacco**	Hookah	Pipe tobacco	Bidis
Estimated no. of current tobacco product users††	4,920,000	3,640,000	1,410,000	1,310,000	1,100,000	740,000	200,000	130,000
Estimated no. of flavored product users††	3,150,000	2,370,000	640,000	570,000	410,000	190,000	50,000	50,000
Prevalence of flavored product use among all students	11.7 (10.6–13.0)	9.0 (7.9–10.2)	2.5 (2.1–2.8)	2.2 (1.9–2.5)	1.6 (1.2–1.9)	0.7 (0.6–1.0)	0.2 (0.1–0.3)	0.2 (0.1–0.3)
Prevalence of flavored product use among current users	64.1 (61.6–66.6)	65.2 (62.6–67.8)	45.7 (42.1–49.4)	43.6 (40.1–47.2)	37.5 (33.0–42.2)	26.1 (21.5–31.2)	26.5 (19.7–34.6)	38.9 (28.7–50.2)
School type								
Middle school	48.7 (43.2–54.2)	51.5 (46.0–57.0)	42.0 (33.4–51.1)	39.4 (29.6–50.2)	28.4 (19.4–39.6)	18.3 (9.8–31.5)	—§§	—
High school	67.4 (64.8–70.0)	67.8 (65.0–70.4)	46.1 (41.9–50.3)	44.5 (40.8–48.3)	40.1 (35.3–45.1)	27.9 (22.7–33.7)	27.3 (18.9–37.6)	35.7 (24.1–49.4)
Sex								
Female	65.4 (62.3–68.4)	65.5 (62.4–68.5)	45.9 (39.7–52.2)	45.8 (40.1–51.6)	29.2 (22.5–36.9)	31.7 (24.5–39.8)	27.4 (16.8–41.4)	—
Male	63.1 (60.0–66.1)	62.5 (59.1–65.7)	45.4 (40.7–50.2)	42.4 (37.7–47.3)	41.2 (36.0–46.7)	20.5 (15.1–27.3)	25.5 (18.0–34.8)	26.3 (15.7–40.7)
Race/Ethnicity								
White, non-Hispanic	71.3 (68.3–74.0)	72.0 (69.0–74.7)	42.8 (37.9–47.8)	49.3 (44.3–54.4)	44.8 (39.3–50.5)	29.9 (21.2–40.4)	23.0 (13.8–35.8)	—
Black, non-Hispanic	46.5 (39.6–53.6)	52.8 (40.1–65.1)	51.4 (32.8–69.7)	39.1 (30.0–48.9)	—	—	—	—
Hispanic	54.3 (50.8–57.9)	49.3 (44.2–54.4)	50.6 (44.1–57.0)	39.2 (33.3–45.5)	22.1 (15.6–30.3)	26.7 (20.3–34.3)	37.0 (24.3–51.8)	—
Other, non-Hispanic	64.4 (57.5–70.8)	68.6 (62.0–74.5)	44.8 (35.0–54.9)	44.2 (30.7–58.5)	31.6 (19.2–47.3)	28.2 (17.3–42.5)	—	—

Abbreviations: CI = confidence interval; e-cigarettes = electronic cigarettes.

* Tobacco products asked about include cigarettes; e-cigarettes; hookahs (water pipes used to smoke tobacco); cigars (defined as cigars, cigarillos, or little cigars); tobacco in pipes; smokeless tobacco (defined as chewing tobacco, snuff, or dip); snus (a smokeless, spitless, tobacco product); dissolvable tobacco products (hereafter referred to as dissolvables); and bidis (small imported cigarettes wrapped in a leaf). Current cigarette smoking was determined by asking "During the past 30 days, on how many days did you smoke cigarettes?" Current use of cigars was determined by asking "During the past 30 days, on how many days did you smoke cigars, cigarillos, or little cigars?" Current use of smokeless tobacco was determined by asking "During the past 30 days, on how many days did you use chewing tobacco, snuff, or dip?" Current use of e-cigarettes was determined by asking "During the last 30 days, on how many days did you use e-cigarettes?" Current use of hookahs was determined by asking "During the past 30 days, on how many days did you smoke tobacco in a hookah or waterpipe?" Current use of pipe tobacco (not hookahs), snus, dissolvable tobacco, and bidis were determined by asking "In the past 30 days, which of the following products have you used on at least one day?"

† Flavored tobacco product use was determined by the response to the question "Which of the following tobacco products that you used in the past 30 days were flavored to taste like menthol (mint), alcohol (wine, cognac), candy, fruit, chocolate, or other sweets?" Participants could select from a list of options to designate the flavored tobacco products they had used. Among those who reported any use of each respective product in the preceding 30 days, those who selected the flavored product were categorized as flavored product users; those who did not select the flavored product were categorized as only nonflavored product users; and those who did not provide any response to the flavored use question were assigned to missing flavor use status.

§ Any tobacco is use of cigarettes, cigars, smokeless tobacco, e-cigarettes, hookahs, pipe tobacco, snus, dissolvables, or bidis on ≥1 day in the preceding 30 days.

¶ Flavored cigarette use refers to menthol cigarettes. Menthol cigarette status was determined by asking "Menthol cigarettes are cigarettes that taste like mint. During the past 30 days, were the cigarettes that you usually smoked menthol?" and "During the past 30 days, what brand or cigarettes did you usually smoke?" Among past 30-day cigarette smokers, those responding "Yes" to the menthol question, or who reported "Newport" or "Kool" as the usual cigarette brand were classified as menthol smokers; subsequently those who reported "No" to the menthol question or who did not report "Newport" or "Kool" brands were classified as nonmenthol smokers; all other past 30-day cigarette smokers were classified as missing menthol smoking status.

** Any smokeless tobacco is current use of smokeless tobacco (chewing tobacco, snuff, or dip), snus, or dissolvables on ≥1 day in the preceding 30 days.

†† The estimated numbers of total and flavored tobacco product users were rounded down to the nearest 10,000.

§§ Dashes indicate data are statistically unreliable because the sample size was <50 or the relative standard error was >30%.

FIGURE. Percentage of current tobacco product*,† users in high school and middle school who reported using flavored products during the preceding 30 days, by tobacco product — National Youth Tobacco Survey, United States, 2014–2018



* For 2014–2015, use of any tobacco is use of cigarettes, cigars, smokeless tobacco, electronic cigarettes, hookahs, pipe tobacco, snus, or dissolvables on ≥1 day in the preceding 30 days. For 2016–2018, use of any tobacco is use of cigarettes, cigars, smokeless tobacco, electronic cigarettes, hookahs, pipe tobacco, snus, dissolvables, or bidis on ≥1 day in the preceding 30 days. Exclusion of bidis from any tobacco use for 2016–2018 did not change the estimates.

† Use of flavored bidis was only asked beginning in 2016, so estimates of flavored bidi use are not available for 2014–2015. For middle school estimates, use of flavored pipe tobacco and bidis are not shown because the individual estimates needed to be suppressed as a result of small sample size, relative standard error >30%, or both.

multiple municipalities in Massachusetts that include menthol among the types of prohibited flavors.[††] In September 2019, Michgan became the first state to ban flavored e-cigarettes, including mint and menthol.[§§] Continued evaluation of the impact of flavored tobacco product policies on tobacco-related behaviors is important, particularly among youths.

The findings in this report are subject to at least four limitations. First, data were collected from youths who attended public or private schools; therefore, the findings might not be generalizable to those who are home-schooled, have dropped out of school, or are in detention centers. Second, flavored tobacco product use was assessed using a check-all-that-apply response option, which might yield different estimates than forced-choice response options. Third, because of known underreporting of menthol cigarette smoking, this analysis relied on responses to menthol and usual brand questions, whereas determination of other flavored tobacco product use relied on a single question. Thus, results might not be directly comparable across products. Finally, NYTS only included use of bidis in the survey during 2016–2018.

On August 8, 2016, FDA finalized its deeming rule, which gave the agency jurisdiction over products made or derived from tobacco, including e-cigarettes, cigars, pipe tobacco, and hookah tobacco (*9*). On March 20, 2018, FDA released an advance notice of proposed rulemaking seeking public input on how best to regulate flavors, including menthol, in tobacco products.[¶¶] In November 2018, FDA announced several new steps to protect youths, including restricting sales of flavored e-cigarettes (other than tobacco, menthol, mint, or nonflavored) to physical locations with age restrictions or online with heightened age verification procedures, and plans to publish advance notices of proposed rulemaking that would ban menthol cigarettes and cigars and all other flavored cigars.[***] Further, FDA published draft guidance in March 2019 outlining a proposal to end the current compliance policy as it applies to flavored electronic nicotine delivery systems; a reprioritization of enforcement efforts will focus on mitigating risk for minors to access these tobacco products.[†††] FDA regulation of the manufacturing, distribution, and marketing of flavored tobacco products, coupled with sustained implementation of comprehensive tobacco control and prevention strategies, can further reduce tobacco product initiation and use among youths (*2*,*10*).

Summary

What is already known about this topic?

Flavored tobacco products can appeal to youths and young adults.

What is added by this report?

During 2014–2018, current use of flavored electronic cigarettes increased among high school students and during 2015–2018 among middle school students. During 2014–2018, current use of flavored hookah tobacco decreased among middle and high school students. Current use of other flavored tobacco products decreased among high school students but did not change among middle school students.

What are the implications for public health practice?

Food and Drug Administration regulation of the manufacturing, distribution, and marketing of flavored tobacco products, coupled with sustained implementation of comprehensive tobacco control and prevention strategies, can further reduce tobacco product use among youths.

[††] https://library.municode.com/mn/minneapolis/codes/code_of_ordinances?nodeId=COOR_TIT13LIBURE_CH281TODE_281.15DE; https://www.eastbaytimes.com/2017/09/20/oakland-bans-flavored-tobacco-products/; https://sfgov.legistar.com/View.ashx?M=F&ID=5274235&GUID=86C18253-BA63-4C0F-A6A0-E881211D2CB7; https://library.municode.com/ca/santa_clara_county/ordinances/code_of_ordinances?nodeId=796084; https://stpaul.legistar.com/LegislationDetail.aspx?ID=3145418&GUID=42F0956E-EBB2-43E4-A74C-76FCC9A9E37C&FullText=1; http://mhoa.com/wp-content/uploads/2018/12/muni-list-Flavored-OTP-Restriction.pdf.

[§§] https://www.washingtonpost.com/health/michigan-becomes-first-state-to-ban-flavored-e-cigarettes/2019/09/03/34f234c6-ce4c-11e9-8c1c-7c8ee785b855_story.html.

[¶¶] https://www.federalregister.gov/documents/2018/03/21/2018-05655/regulation-of-flavors-in-tobacco-products.

[***] https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-proposed-new-steps-protect-youth-preventing-access.

[†††] https://www.fda.gov/regulatory-information/search-fda-guidance-documents/modifications-compliance-policy-certain-deemed-tobacco-products.

Corresponding author: Karen A. Cullen, karen.cullen@fda.hhs.gov; 240-402-4513.

[1]Center for Tobacco Products, Food and Drug Administration, Silver Spring, Maryland; [2]Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion, CDC.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

References

1. US Department of Health and Human Services. Preventing tobacco use among youth and young adults: a report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, CDC; 2012. https://www.ncbi.nlm.nih.gov/books/NBK45031/
2. CDC. Best practices for comprehensive tobacco control programs–2014. Atlanta, GA: US Department of Health and Human Services, CDC; 2014. https://www.cdc.gov/tobacco/stateandcommunity/best_practices/index.htm
3. US Department of Health and Human Services. E-cigarette use among youth and young adults. a report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, CDC; 2016. https://e-cigarettes.surgeongeneral.gov/documents/2016_sgr_full_report_non-508.pdf

4. National Academies of Sciences, Engineering, and Medicine. Public health consequences of e-cigarettes. Washington, DC: The National Academies Press; 2018. https://www.nap.edu/catalog/24952/public-health-consequences-of-e-cigarettes
5. Morris DS, Fiala SC. Flavoured, non-cigarette tobacco for sale in the USA: an inventory analysis of Internet retailers. Tob Control 2015;24:101–2. https://doi.org/10.1136/tobaccocontrol-2013-051059
6. King BA, Gammon DG, Marynak KL, Rogers T. Electronic cigarette sales in the United States, 2013–2017. JAMA 2018;320:1379–80. https://doi.org/10.1001/jama.2018.10488
7. Willett JG, Bennett M, Hair EC, et al. Recognition, use and perceptions of JUUL among youth and young adults. Tob Control 2019;28:115–6.
8. Rogers T, Brown EM, McCrae TM, et al. Compliance with a sales policy on flavored non-cigarette tobacco products. Tob Regul Sci 2017;3(Suppl 1):84–93. https://doi.org/10.18001/TRS.3.2(Suppl1).9
9. Food and Drug Administration. Deeming tobacco products to be subject to the federal food, drug, and cosmetic act, as amended by the family smoking prevention and tobacco control act; regulations on the sale and distribution of tobacco products and required warning statements for tobacco products. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2016. https://www.federalregister.gov/documents/2016/05/10/2016-10685/deeming-tobacco-products-to-be-subject-to-the-federal-food-drug-and-cosmetic-act-as-amended-by-the
10. US Department of Health and Human Services. The health consequences of smoking: 50 years of progress. a report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, CDC; 2014. https://www.hhs.gov/surgeongeneral/reports-and-publications/tobacco/index.html

Trends and Characteristics in Marijuana Use Among Public School Students — King County, Washington, 2004–2016

Myduc Ta, PhD[1]; Lindsey Greto, MPA[2]; Kaylin Bolt, MPH, MSW, MEd[1]

Use of marijuana at an early age can affect memory, school performance, attention, and learning; conclusions have been mixed regarding its impact on mental health conditions, including psychosis, depression, and anxiety (*1*–*3*). Medical marijuana has been legal in Washington since 1998, and in 2012, voters approved the retail sale of marijuana for recreational use to persons aged ≥21 years. The first retail stores opened for business in July 2014. As more states legalize marijuana use by adults aged ≥21 years, the effect of legalization on use by youths will be important to monitor. To guide planning of activities aimed at reducing marijuana use by youths and to inform ongoing policy development, Public Health—Seattle & King County assessed trends and characteristics of past 30–day marijuana use among King County, Washington, public school students in grades 6, 8, 10, and 12. This report used biennial data for 2004–2016 from the Washington State Healthy Youth Survey. Among grade 6 students there was a decreasing trend in self-reported past 30–day marijuana use from 2004 to 2016, while the percentage of grade 8 students who had used marijuana during the past 30 days did not change during that period. Among students in grades 10 and 12, self-reported past 30–day use of marijuana increased from 2004 to 2012, then declined from 2012 to 2016. In 2016, the percentage of students with past 30–day marijuana use in King County was 0.6% among grade 6, 4.1% among grade 8, 13.9% among grade 10, and 25.5% among grade 12 students. Among grade 10 students, 24.0% of past 30–day marijuana users also smoked cigarettes, compared with 1.3% of nonusers. From 2004 to 2016 the prevalence of perception of great risk of harm from regular marijuana use decreased across all grades. Continued surveillance using consistent measures is needed to monitor the impact of marijuana legalization and emerging public health issues, given variable legislation approaches among jurisdictions.

The Healthy Youth Survey is a school-based, anonymous, self-administered, cross-sectional survey conducted in the fall of even-numbered years in Washington public schools.* Schools with grades 6, 8, 10, and 12 are randomly selected using a clustered sampling design. Schools not selected for the state sample also can choose to participate in the survey. The survey measures risk behaviors, attitudes, and factors that contribute to youth health and safety, including alcohol, marijuana, tobacco, and other drug use; behaviors that result in unintentional and intentional injuries (e.g., violence); dietary behaviors, and physical activity.

This analysis used data from all participating schools, both sampled and nonsampled, representing all 19 King County school districts for biennial survey years 2004 through 2016 (the most currently available year of data at the time of analysis). King County is the largest metropolitan county in the state. Local jurisdictions have authority to regulate land uses and can impose additional time, place, and manner-of-use restrictions on state licensed businesses; thus, considerable variation in the availability of and restrictions on retail marijuana exists across the 39 cities in King County, including Seattle.

Survey response rates varied by grade and survey year, with higher rates in more recent surveys.† During 2004–2016, King County response rates ranged from 60%–80% for grades 6 and 8; 50%–70% for grade 10; and 40%–50% for grade 12. For the 2016 survey, response rates for King County were 80% for grades 6 and 8, 70% for grade 10, 40% for grade 12, and 67% for all grades combined.

Data representing substance use, perception of great risk of harm, risky behaviors, and factors associated with marijuana use were categorized dichotomously. Past 30–day marijuana use was considered use on 1 or more days during the past 30 days. Perceived great risk of harm associated with regular marijuana use (more than one or two times per week) was categorized dichotomously as great risk versus all other options combined (moderate, slight, and no perceived risk). Past 30–day use of alcohol, cigarettes, and electronic cigarettes/vape pens was considered use on 1 or more days in the past 30 days, past 30–day risky driving and riding behaviors,§ were considered one or more occurrences during the past 30 days and past binge drinking¶ was over a 2-week period.

* https://www.doh.wa.gov/DataandStatisticalReports/DataSystems/HealthyYouthSurvey/TechnicalNotes.

† During the analysis period, two south King County school districts had inconsistent participation: one district did not participate in 2008 and 2010, and the other district did not participate in 2004. A third school district has not participated since 2004 because of small enrollment (<40 students districtwide).

§ Driving within 3 hours of using marijuana and risky riding defined as riding with a driver who had used marijuana.

¶ Consuming five or more drinks in a row in the past 2 weeks.

Dichotomous factors generally reported to be associated with other substance use (*4*) were examined for marijuana use; these factors included whether students' parents had talked about not using marijuana, use by one or more best friends or by a member in the youth's household, and having been bullied one or more times in the past month.** Stata survey software (version 13; StataCorp) was used to generate percentage estimates and corresponding 95% confidence intervals (CIs). To account for differential participation among school districts across survey years, percentage estimates were weighted to the school district total enrollment by grade and sex, with the final weights adjusted to sum to the county total public school enrollment by grade and sex. Joinpoint trend analysis software (https://surveillance.cancer.gov/joinpoint/) was used to evaluate statistical significance of trends in survey-weighted percentage estimates by grade and sex. Analyses of trends by sex and examination of factors associated with past 30–day use were restricted to grade 10 students as a result of grade-specific sampling and the need for adequate response rates to accommodate a robust analysis.

During 2004–2016, the prevalence of reported past 30–day marijuana use was lowest among students in grade 6 and increased with school grade level (Figure 1). In 2016, past 30–day marijuana use was reported by 0.6% (CI = 0.4–0.7)

** https://www.drugabuse.gov/publications/preventing-drug-abuse-among-children-adolescents/chapter-1-risk-factors-protective-factors and https://iprc.iu.edu/spf/docs/Risk%20and%20Protective%20Factors%20Associated%20with%20Youth%20Marijuana.pdf.

FIGURE 1. Percentage of students with past 30–day (current) marijuana use* and their perception of great risk of harm† associated with marijuana use, by school grade — Healthy Youth Survey, King County, Washington, 2004–2016



* Significant decreasing trend (p<0.05) in past 30-day marijuana use for grade 6. Change in trend starting in 2012 for grades 10 and 12.
† Significant decreasing trend (p<0.05) in perception of great risk of harm from marijuana use for all grades.

of grade 6 students, 4.1% (CI = 3.5–4.8) of grade 8 students, 13.9% (CI = 12.6–15.3) of grade 10 students, and 25.5% (CI = 23.7–27.4) of grade 12 students in King County. Among students in grade 6, past 30–day marijuana use declined significantly, from 1.3% in 2004 to 0.6% in 2016. There was no statistically significant trend among students in grade 8; however, among students in grades 10 and 12, past 30–day use increased from 2004 to 2012, and then declined. Across all grades, the percentage of students reporting great risk of harm from regular marijuana use declined over the survey period, with the lowest perceived great risk of harm reported among older students in all years. In 2016, 26.7% (CI = 25.0–28.5) of students in grade 12 perceived great risk of harm from regular marijuana use, whereas 53.3% (CI = 50.5–56.1) reported this perception in 2004.

Among male students in grade 10, past 30–day marijuana use increased from 17.6% in 2004 to 21.4% in 2010 and subsequently declined to 13.5% in 2016 (Figure 2). Among female students in grade 10, there was no change in the prevalence of past 30–day use, which remained approximately 16% during this period. In 2016, there was no significant difference in past 30–day marijuana use between male and female students in grade 10.

Among past 30–day marijuana users in grade 10, 42.8% reported living with someone who uses marijuana, 88.5% reported having at least one best friend who used marijuana, and 26.3% reported having been bullied at least once in the past 30 days; these prevalences were higher than those among grade 10 nonusers (12.8%, 28.3%, and 16.5%, respectively) (Table). Among grade 10 marijuana users, 92.5% reported that it was not very hard to obtain marijuana, compared with 56.7% of nonusers. No parental discussion about marijuana during the past year was reported by similar percentages of past 30–day marijuana users (39.2%) and nonusers (39.8%).

Among grade 10 students, prevalence of past 30–day use of other substances was four times higher among those who had

FIGURE 2. Percentage of students who were past 30–day (current) marijuana users among grade 10 students, by sex — Healthy Youth Survey, King County, Washington, 2004–2016*



* Significant ($p<0.05$) change in trend among male grade 10 students starting in 2010.

TABLE. Prevalence of marijuana use among 10th grade public school students in the past 30 days and prevalence ratios between marijuana users and nonusers, by selected characteristics (N = 14,055) — Healthy Youth Survey, King County, Washington, 2016

Characteristic	Marijuana use in past 30 days*		
	Yes (n = 1,949) % (95% CI)	No (n = 12,106) % (95% CI)	Prevalence ratio marijuana users/ nonusers (95% CI)
Overall	**13.9 (12.6–15.3)**	**86.1 (84.7–87.4)**	**N/A**
Individual/Family factors†			
Household marijuana use§	42.8 (39.2–46.5)	12.8 (11.4–14.4)	3.3 (2.9–3.9)
Parents have not talked about not using marijuana	39.2 (36.1–42.3)	39.8 (38.1–41.4)	1.0 (0.9–1.1)
≥1 best friend who used marijuana	88.5 (85.7–90.8)	28.3 (26.1–30.6)	3.1 (2.9–3.4)
Perceived great risk of harm from regular marijuana use	8.1 (6.6–9.8)	45.0 (42.5–47.5)	0.18 (0.15–0.22)
Not very hard to get marijuana	92.5 (90.8–93.9)	56.7 (54.8–58.6)	1.6 (1.6–1.7)
At academic risk¶	35.5 (31.4–39.7)	15.1 (13.2–17.2)	2.4 (2.1–2.7)
Bullied ≥1 time in past 30 days	26.3 (23.8–28.9)	16.5 (15.5–17.6)	1.6 (1.4–1.8)
Driving within 3 hours of using marijuana at least once in the past month	36.0 (31.7–40.6)	N/A	N/A
Rode in car at least once in the past month with driver who has used marijuana	60.8 (56.7–64.7)	6.8 (5.8–7.9)	9.0 (7.8–10.3)
Additional substance use**			
Alcohol	67.0 (63.9–70.0)	10.3 (9.5–11.2)	6.5 (6.0–7.0)
Cigarette smoking	24.0 (21.4–26.7)	1.3 (1.1–1.5)	18.9 (16.1–22.0)
E-cigarettes/Vape pens	43.0 (37.4–48.8)	4.0 (3.3–4.7)	10.9 (9.3–12.7)
Binge drinking††	43.5 (40.4–46.7)	3.7 (3.3–4.1)	11.9 (10.5–13.5)
Any substance use§§	88.6 (86.6–90.3)	22.1 (20.6–23.7)	4.0 (3.7–4.3)

Abbreviations: CI = confidence interval; N/A = Not applicable.

* All estimates are survey weighted to reflect total county public school enrollment by grade and sex; prevalence ratios are unadjusted comparing marijuana users and nonusers for individual or family factors and additional substance use.

† Marijuana users and nonusers who reported a given individual or family factor. Denominators for categories listed might be less than total marijuana users and non-users because some respondents only responded to the marijuana use question.

§ Lives with someone who uses marijuana.

¶ Grades of "C" or lower.

** Marijuana users and nonusers who reported using other substances on 1 or more days in the past 30 days. Denominators for categories listed might be less than total marijuana users and non-users because some respondents only responded to the marijuana use question.

†† Consumed five or more alcoholic drinks in a row during the preceding 2 weeks.

§§ Reported use of alcohol, cigarette smoking, or e-cigarette/vape pen on one or more days in the past 30 days, or reported binge drinking.

used marijuana in the past 30 days than among those who had not. Among marijuana users, the prevalences of past 30–day use of other substances were as follows; alcohol (67.0%), cigarettes (24.0%), e-cigarettes or vape pens (43.0%), and of binge drinking (43.5%), compared with 10.3%, 1.3%, 4.0%, and 3.7% among nonusers, respectively. Among grade 10 marijuana users, 36% reported driving within 3 hours of using marijuana at least once in the past month.

Discussion

Despite legalization of the retail sale of marijuana to adults in Washington in 2012, evidence from the biennial Washington State Healthy Youth Survey indicates that the prevalence of past 30–day marijuana use among students in grades 10 and 12 began to decline that year. The decline continued in 2016 among grade 10 students and did not change significantly among grade 12 students. This decline or absence of change in youth marijuana use after legalization of retail sales to adults is consistent with trends reported in Colorado and Oregon,†† states that legalized adult retail sales of marijuana in 2013 and 2014, respectively. However, causality of the observed decrease in youth use following retail sale legalization cannot be inferred, because effects might be delayed and this report does not include data from the timeframe that would capture the more recent surge in e-cigarette use by youth and the use of tetrahydrocannabinol (THC) within electronic cigarette (e-cigarette) devices. Although the relationship between legal adult recreational use and youth use is not well understood, two possible reasons for the observed decline in youth use include reduction of illicit market supply through competition§§ and loss of novelty appeal among youths. Furthermore, it would be important to monitor the long-term role legalization might play to foster a permissive use environment given observed strong associations with use and individual and family factors that influence youth use.

Before initiation of retail marijuana sales in Washington in 2014, the statewide prevalence of use among grade 10 students had not changed significantly since 2002, although reported

†† https://www.colorado.gov/cdphe/marijuana-health-report and https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/MARIJUANA/Documents/HB3400-Legislative-Report-Youth-Prevention-2017.pdf.

§§ https://www.wsipp.wa.gov/ReportFile/1670/Wsipp_I-502-Evaluation-and-Benefit-Cost-Analysis-Second-Required-Report_Report.pdf.

Summary

What is already known about this topic?

Youth marijuana use can have adverse health outcomes. However, reports from Colorado, Oregon, and Washington indicate no statewide increase in youth marijuana use following retail legalization for adults.

What is added by this report?

Following 2012 legalization of retail marijuana sale to adults in Washington, past 30–day marijuana use decreased or remained stable through 2016 among King County students in grades 6, 8, 10, and 12. Among grade 10 students, the decline in use occurred among males while the rate among females remained steady. Use of alcohol or other substances was four times as frequent among marijuana users as among nonusers.

What are the implications for public health practice?

Understanding reasons for youth marijuana use, particularly among females, might help inform policy, strategies, and educational campaigns.

statewide use prevalence in 2016 was higher among students identifying as non-Hispanic American Indian/Alaska Native and Hispanic than among non-Hispanic white and non-Hispanic Asian students (*5*). Among grade 10 King County students, past 30–day marijuana use by male students has been decreasing since 2010, while the prevalence among female students has not changed. Continued monitoring is necessary to observe how local trends among males change over time. The narrowing of the sex difference gap reflects national trends (*6*) and suggests that female users might benefit from tailored prevention messages informed by an understanding of reasons for use.

Although overall youth rates of smoking and alcohol are declining nationally (*7*), the prevalence of any substance use, including alcohol, cigarettes, or vape pens, was four times higher among grade 10 past 30–day marijuana users than among nonusers. Statewide data from 2016 also show similar higher prevalence of household, peer and individual factors associated with youth substance use among grade 10 marijuana users than nonusers (https://www.askhys.net/library/2016/RecentMarijaunaUseGr10.pdf). Findings from a 2017 survey of Canadian residents aged 15–24 years found that marijuana users were significantly more likely to be past 30-day e-cigarette users, compared with nonusers (*8*). Polysubstance use and driving after using marijuana or riding in a car driven by someone who had used marijuana recently are public health issues that are important to monitor. Educational campaigns conveying health risk of marijuana use should also address impaired driving, in light of experimental data showing deteriorating control with increasing task complexity and increased risk for involvement in a motor vehicle crash (*9*).

The findings in this report are subject to at least six limitations. First, these data predate the recent reported increase in youth e-cigarette use and the use of THC in the newest generation of e-cigarette devices. The marijuana use question does not explicitly define use by method and estimates of youth marijuana use might be underestimated if respondents did not consider vaping or edible consumption of marijuana products when responding to the question. Second, data are from public school students only and might not be generalizable to all youths in this age group. Students who might be at higher risk might not be in school; it is estimated that 95.3% of King County residents aged 14–18 years are in school.[¶¶] Third, survey participation is voluntary, and responses are based on self-report, which can be subject to recall or response bias. Fourth, these estimates might differ from other state or nationally representative youth health–surveillance systems, in part because of survey methods, age of participants, survey setting, and period during the year the survey was conducted. Fifth, local historical data for youth marijuana use before 2004 are not available, and the effects of medical marijuana legalization, which occurred in 1998, on use by youths is unknown. Finally, binge drinking is framed as five or more drinks in a row during the preceding 2 weeks for both males and females and would likely underestimate excessive alcohol consumption among females compared with using a sex-specific four-drink threshold (*10*).

The national goals for substance use set by Healthy People 2020[***] include a target of 6% for youths aged 12–17 years with past 30–day marijuana use, and progress toward this target requires evidence-based interventions and policies for preventing and treating substance use and abuse among youths. Although some cross-cutting interventions addressing adolescent health are presented in the Community Preventive Task Force's Community Guide,[†††] there currently is no specific category for marijuana use, as there is for alcohol and tobacco. The National Registry of Evidence-based Programs and Practices,[§§§] a project of the federal Substance Abuse and Mental Health Services Administration, might be a potential alternative source for strategies that reduce marijuana use and prevent associated harms, but these strategies might not be sufficient for states with newly legalized retail marketplaces.

[¶¶] Based on analysis of 2012–2016 U.S. Census Bureau American Community Survey Public Use Microsample data, 95.3% (95% CI = 94.4%–96%) of the King County population aged 14–18 years are in school; 98% (95% CI = 97.3%–98.6%) of the King County population aged 15–16 years (grade 10) are in school.

[***] https://www.healthypeople.gov/2020/topics-objectives/topic/substance-abuse.

[†††] https://www.thecommunityguide.org; https://www.healthypeople.gov/2020/tools-resources/Evidence-Based-Resources.

[§§§] https://www.samhsa.gov/ebp-resource-center.

In light of the limited evidence base, there is a need to identify individual, relationship, community, and societal determinants of youth substance use that would allow development of broad-based risk-reduction strategies. Continued surveillance would benefit from having a set of standard measures across jurisdictions to monitor the health impacts of retail marijuana sale legalization among states.

Acknowledgment

Eva Wong, Assessment, Policy Development & Evaluation Unit, Public Health—Seattle & King County, Washington.

Corresponding author: Myduc Ta, myduc.ta@kingcounty.gov, 206-263-8772.

[1]Assessment, Policy Development & Evaluation Unit, Public Health—Seattle & King County, Washington; [2]Youth Marijuana Prevention and Education Program, Chronic Disease & Injury Prevention Division, Public Health—Seattle & King County, Washington.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

References

1. National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: current state of evidence and recommendations for research. Washington, DC: The National Academies Press; 2017.
2. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A 2012;109:E2657–64. https://doi.org/10.1073/pnas.1206820109
3. Dougherty DM, Mathias CW, Dawes MA, et al. Impulsivity, attention, memory, and decision-making among adolescent marijuana users. Psychopharmacology (Berl) 2013;226:307–19. https://doi.org/10.1007/s00213-012-2908-5
4. Whitesell M, Bachand A, Peel J, Brown M. Familial, social, and individual factors contributing to risk for adolescent substance use. J Addict 2013;2013:579310. https://doi.org/10.1155/2013/579310
5. Shah A, Stahre M. Marijuana use among 10th grade students—Washington, 2014. MMWR Morb Mortal Wkly Rep 2016;65:1421–4. https://doi.org/10.15585/mmwr.mm655051a1
6. Johnson RM, Fairman B, Gilreath T, et al. Past 15-year trends in adolescent marijuana use: differences by race/ethnicity and sex. Drug Alcohol Depend 2015;155:8–15. https://doi.org/10.1016/j.drugalcdep.2015.08.025
7. Kann L, McManus T, Harris WA, et al. Youth Risk Behavior Surveillance—United States, 2015. MMWR Surveill Summ 2016;65(No. SS-6).
8. Mehra VM, Keethakumar A, Bohr YM, Abdullah P, Tamim H. The association between alcohol, marijuana, illegal drug use and current use of e-cigarette among youth and young adults in Canada: results from Canadian Tobacco, Alcohol and Drugs Survey 2017. BMC Public Health 2019;19:1208. https://doi.org/10.1186/s12889-019-7546-y
9. Hartman RL, Huestis MA. Cannabis effects on driving skills. Clin Chem 2013;59:478–92. https://doi.org/10.1373/clinchem.2012.194381
10. Chavez PR, Nelson DE, Naimi TS, Brewer RD. Impact of a new gender-specific definition for binge drinking on prevalence estimates for women. Am J Prev Med 2011;40:468–71. https://doi.org/10.1016/j.amepre.2010.12.008

Evaluation of Infection Prevention and Control Readiness at Frontline Health Care Facilities in High-Risk Districts Bordering Ebola Virus Disease–Affected Areas in the Democratic Republic of the Congo — Uganda, 2018

Caitlin Biedron, MD[1,2]; Meghan Lyman, MD[2]; Matthew J. Stuckey, PhD[2]; Jaco Homsy, MD[3]; Mohammed Lamorde, PhD[4]; Ulzii-Orshikh Luvsansharav, PhD[2]; Kathryn Wilson, MPH[2]; Danica Gomes, MD[2]; Winifred Omuut, MPH[4]; Solome Okware, MD[4]; Judith Nanyondo Semanda, MPH[4]; Reuben Kiggundu, MBChB[4]; Daniel Bulwadda, MMED[4]; Vance Brown, MA[3]; Lisa J. Nelson, MD[3]; Alfred Driwale, MBChB[5]; Ryan Fagan, MD[2]; Benjamin J. Park, MD[2]; Rachel M. Smith, MD[2]

Infection prevention and control (IPC) in health care facilities is essential to protecting patients, visitors, and health care personnel from the spread of infectious diseases, including Ebola virus disease (Ebola). Patients with suspected Ebola are typically referred to specialized Ebola treatment units (ETUs), which have strict isolation and IPC protocols, for testing and treatment (*1*,*2*). However, in settings where contact tracing is inadequate, Ebola patients might first seek care at general health care facilities, which often have insufficient IPC capacity (*3*–*6*). Before 2014–2016, most Ebola outbreaks occurred in rural or nonurban communities, and the role of health care facilities as amplification points, while recognized, was limited (*7*,*8*). In contrast to these earlier outbreaks, the 2014–2016 West Africa Ebola outbreak occurred in densely populated urban areas where access to health care facilities was better, but contact tracing was generally inadequate (*8*). Patients with unrecognized Ebola who sought care at health care facilities with inadequate IPC initiated multiple chains of transmission, which amplified the epidemic to an extent not seen in previous Ebola outbreaks (*3*–*5*,*7*). Implementation of robust IPC practices in general health care facilities was critical to ending health care–associated transmission (*8*). In August 2018, when an Ebola outbreak was recognized in the Democratic Republic of the Congo (DRC), neighboring countries began preparing for possible introduction of Ebola, with a focus on IPC. Baseline IPC assessments conducted in frontline health care facilities in high-risk districts in Uganda found IPC gaps in screening, isolation, and notification. Based on findings, additional funds were provided for IPC, a training curriculum was developed, and other corrective actions were taken. Ebola preparedness efforts should include activities to ensure that frontline health care facilities have the IPC capacity to rapidly identify suspected Ebola cases and refer such patients for treatment to protect patients, staff members, and visitors.

The Ebola outbreak in DRC was declared on August 1, 2018. As of September 22, 2019, a total of 3,168 probable and laboratory-confirmed cases had been reported in the outbreak, 3,162 (99%) of which were reported from North Kivu (Nord-Kivu) and Ituri provinces, in the northeastern part of the country, bordering Uganda (*9*). Six additional cases have been reported from South Kivu (Sud-Kivu), which borders Rwanda and Burundi (*9*). Health care personnel have accounted for 160 (5%) cases (*9*). Cases initially were confirmed in Mandima health zone in Ituri province, but the epicenter of the outbreak subsequently moved southward through North Kivu, to the Beni, Katwa, and Butembo health zones, where the majority of cases are currently being reported (*9*). Cases continue to be identified across a large swath of territory spanning Ituri, North Kivu and South Kivu provinces, and outbreak control has been hampered by population mobility, insecurity, and community mistrust of response activities. Official and unofficial cross-border movement between Ituri and North Kivu provinces and Uganda occurs for trade, family visitation, movement of refugees, and medical care, increasing the risk for importation of Ebola into Uganda.

In August 2018, baseline IPC assessments were performed with a convenience sample of four health care facilities in Uganda selected because of their proximity to the focus of the Ebola outbreak in DRC. Institutional review board review was not performed for this activity because the IPC assessments were part of a public health program evaluation in an emergency response. The facilities included one regional referral hospital, two district hospitals, and one Level IV health center. Assessment teams included staff members from district health offices, Makerere University's Infectious Disease Institute (IDI), and U.S. CDC. Upon arrival at the facility, assessment teams first met with the medical director to explain the assessment. Interviews, using a semistructured questionnaire,* were then conducted with the frontline health care personnel (including the IPC nurse-in-charge or main IPC focal point for the facility, physicians, nurses, and environmental cleaners) responsible for conducting screening, isolation, and notification procedures. The assessments also included examination of the facility and observation of practices and focused on a facility's readiness to

* The IPC assessment questionnaire used during this activity was modified from assessment tools previously used by CDC staff members during the West Africa Ebola outbreak. The questionnaire has not been formally validated or piloted. Engagement and informal interviews with health care workers occurred during the assessment process to determine if the facility's capacity in each of the domains was adequate.

prevent Ebola transmission. Capacity in three major domains was assessed: 1) safe and systematic screening and identification of patients with signs and symptoms of Ebola; 2) isolation of any patient meeting the case definition for suspected Ebola; and 3) reporting of patients with suspected Ebola to the required public health authorities. Other general IPC practices were also assessed, including hand hygiene, proper use of personal protective equipment (PPE), and waste disposal. The assessment tool comprised a list of questions within each of the major domains and included observations of current facility isolation and screening practices, if possible. Additional open-ended questions were included to probe further into findings identified in the structured portion of the questionnaire.

Within the screening domain, the assessment focused on determining the location of the screening station, assessing availability of screening supplies, reviewing social distancing practices and use of a standardized case definition, and assessing the capacity of screening staff members. The assessment of isolation focused on ascertaining the availability of IPC consumables and other supplies, reviewing the suitability of the isolation area layout and the designated PPE donning and doffing areas, assessing whether the chlorine dilution process was performed properly, reviewing appropriate waste disposal, and assessing the level of training of health care personnel caring for isolated patients. Within the notification domain, the assessment focused on whether staff members were aware of the proper public health authority to contact when a suspected case was identified, whether a posted list of contact numbers for the district health office was available, and whether a functional mobile phone with adequate phone credit had been provided to staff members.

The assessments were conducted at facilities in Bundibugyo, Kabarole, and Kasese districts, in western Uganda (Figure). Assessment results indicated that IPC preparedness was lacking in several important areas within each of the three domains (Table). Safe and systematic screening was hindered by use of multiple case definitions, improper use of infrared thermometers, and poor adherence to social distancing measures when screening patients. Facility isolation capacity was affected by shortages of IPC consumables such as PPE, training gaps among staff members, and absence of a clear case management and referral plan (i.e., how suspected patients would move from frontline facilities to ETUs). In some facilities, isolation areas were currently in use and several deviations from best practices were seen, including patients with suspected Ebola being unattended, improper chlorine dilution, and improper disposal of PPE and other waste. The assessment team also noted that several of the facilities were in the process of building structures intended to become ETUs; however, these facilities did not have functional isolation areas for suspected Ebola patients

FIGURE. Location of Ebola virus disease outbreaks and frontline health care facilities conducting baseline infection prevention and control (IPC) assessments — Democratic Republic of the Congo (DRC)–Uganda border region, 2018



who might come to the facility for general health care while the ETUs were still in the process of being built. Similarly, training for health care personnel was primarily focused on ETU-related IPC and case management and not on recommended screening and isolation procedures for general health care facilities. In terms of notification practices, most staff members were aware that a district rapid response team existed; however, they had not been informed of which number to call if a suspected Ebola case was identified and contact numbers for the district health office were not clearly posted.

Discussion

A summary of the baseline IPC assessment findings was presented during the Ebola National Task Force meeting held on August 22, 2018, to Uganda Ministry of Health (MOH)

TABLE. Infection prevention and control (IPC) evaluation domains assessed and gaps identified in four health care facilities — Bundibugyo, Kabarole, and Kasese districts, Uganda, August, 2018

Components assessed	Gaps identified
Screening	
Location of screening station	—*
Availability and proper use of supplies	Improper use of infrared thermometers
Social distancing practices†	Poor adherence to social distancing measures
Use of a standardized case definition	Use of multiple case definitions
Staff member capacity	Gaps in training
Isolation	
Availability and proper use of supplies§	Shortage of PPE
Suitability of layout	Lack of functional isolation areas for persons seeking general health care; unattended patients with suspected Ebola
PPE donning and doffing areas	—*
Quality of chlorine preparation	Improper chlorine dilution
Waste disposal	Improper PPE and waste disposal
Staff member training	Absence of clear case management plan
Notification	
Knowledge of how to contact public health authority	Staff members not informed of number to call when a suspected case is identified
Availability of posted contact numbers	Contact numbers for district health officers not posted
Availability of functional mobile phone	—*
Adequate phone credit	—*

Abbreviation: ETU = Ebola virus disease treatment unit; PPE = personal protective equipment.
* No gaps identified.
† Social distancing refers to maintaining a proper distance (usually recommended to be 1–2 m) between persons (e.g., the health care provider and the patient being screened).
§ IPC supplies include infrared thermometers, PPE (gloves, mask, gown, and shoe coverings), supplies for hand-washing station (water, soap, and paper towels), chlorine, plastic container with lid for chlorine, waste bins, bin liners, and sharps boxes.

staff members and other stakeholders present at the meeting. Based on the findings, the National Task Force identified additional funds to purchase needed IPC supplies. Furthermore, the Uganda MOH, CDC, and Makerere University's IDI developed a training curriculum targeting the identified IPC weaknesses and a strategy to provide IPC mentorship to priority health care facilities within high-risk districts. An initial training of 23 national and district mentors was conducted on September 12, 2018, focused on screening, isolation, and notification of patients with suspected Ebola and other IPC topics. The national mentors who attended the training included representatives from the Uganda MOH, staff members from IDI, and clinicians from other district hospitals who had received previous IPC training. District health officers from a subset of high-risk districts also participated in the training. Mentorship teams that included one national mentor and one district mentor were created. Mentors have begun performing on-site mentorship at priority facilities to set up screening and isolation areas and to ensure that facilities are conducting appropriate screening, isolation, and notification. Training materials and curricula have been shared with partners in Rwanda and South Sudan to strengthen Ebola IPC preparedness in other countries neighboring DRC. In addition, this preparedness work is consistent with the capabilities that Uganda has been building under the Global Health Security Agenda and the International Health Regulations framework.

The southward spread of confirmed Ebola cases in late 2018 to the Butembo and Katwa health zones of DRC identified additional high-risk districts in Uganda; trainings of mentors and health care personnel have now been conducted in Kanungu and Kisoro districts. On June 11, 2019 the Uganda MOH confirmed the initial cluster of three Ebola cases in Kasese district (*10*). One additional Ebola case was confirmed shortly after identification of this initial cluster (*9*). Subsequently, an additional round of training for 25 mentors in the Kasese district was led by IDI and scaled up to cover 117 facilities with a goal of reinforcing IPC preparedness and improving practice. As of September 27, 2019, no additional Ebola cases have been identified in Uganda, but the extension of the outbreak into Uganda underscores the need to maintain high levels of IPC preparedness throughout districts bordering affected health zones in DRC.

The findings in this report are subject to at least two limitations. First, only four facilities were assessed during this evaluation and a convenience sample was used. Given the limited sample size and that facilities were not randomly selected, the findings might not be representative of the IPC practices at other health care facilities in the region and might not be generalizable. Second, not all facilities were actively isolating patients with suspected Ebola at the time of the assessment; therefore, certain IPC practices could not be observed. However, at such sites, the staff members were asked how they would perform certain IPC activities if a suspected Ebola patient were to be admitted.

Summary

What is already known about this topic?

The 2014–2016 West Africa Ebola virus disease (Ebola) outbreak demonstrated the importance of strengthening infection prevention and control (IPC) capacity at frontline health care facilities to prevent health care–associated transmission.

What is added by this report?

IPC assessments were performed in four frontline health care facilities in Uganda shortly after an Ebola outbreak in neighboring Democratic Republic of the Congo was recognized. Recommendations were made to address identified gaps in screening, isolation, and notification practices.

What are the implications for public health practice?

Ebola preparedness should include a focus on ensuring that general health care facilities have the capacity to rapidly identify suspected Ebola cases and refer patients for treatment to protect patients, staff members, and visitors.

Ebola outbreaks necessitate rapid scale-up of IPC preparedness activities at facilities where the risk for encountering patients with Ebola is high. Although planning for the establishment of well-run, functional ETUs is a critical aspect of Ebola preparedness, IPC readiness at frontline general health care facilities is also critical to preventing the spread of disease and propagation of outbreaks. Recognition of this necessity in Uganda led to the rapid development and implementation of a plan to enable general health care facilities to promptly identify patients with suspected Ebola and refer them for appropriate management. Close collaboration between the Uganda MOH and district health offices has also been critical, and ongoing engagement of district health officers will be needed for coordination of local mentorship activities and sustainability of IPC preparedness efforts.

Acknowledgments

James Fuller, Robert Neurath.

Corresponding author: Caitlin Biedron, goo9@cdc.gov, 404-345-1340.

[1]Epidemic Intelligence Service, CDC; [2]Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, CDC; [3]CDC Uganda, Center for Global Health, CDC; [4]Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda; [5]Uganda Ministry of Health, Clinical Services, Kampala, Uganda

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

References

1. Kerstiëns B, Matthys F. Interventions to control virus transmission during an outbreak of Ebola hemorrhagic fever: experience from Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999;179(Suppl 1):S263–7. https://doi.org/10.1086/514320
2. Sterk E. Filovirus haemorrhagic fever guidelines. Geneva, Switzerland: Médecins Sans Frontières; 2008. https://www.medbox.org/preview/53f1e3e2-a078-464d-ba8e-257e1fcc7b89/doc.pdf
3. Nyenswah T, Fallah M, Sieh S, et al. Controlling the last known cluster of Ebola virus disease—Liberia, January–February 2015. MMWR Morb Mortal Wkly Rep 2015;64:500–4.
4. Kilmarx PH, Clarke KR, Dietz PM, et al. Ebola virus disease in health care workers—Sierra Leone, 2014. MMWR Morb Mortal Wkly Rep 2014;63:1168–71.
5. Matanock A, Arwady MA, Ayscue P, et al. Ebola virus disease cases among health care workers not working in Ebola treatment units—Liberia, June–August, 2014. MMWR Morb Mortal Wkly Rep 2014;63:1077–81.
6. Casillas AM, Nyamathi AM, Sosa A, Wilder CL, Sands H. A current review of Ebola virus: pathogenesis, clinical presentation, and diagnostic assessment. Biol Res Nurs 2003;4:268–75. https://doi.org/10.1177/1099800403252603.
7. Hageman JC, Hazim C, Wilson K, et al. Infection prevention and control for Ebola in health care settings—West Africa and United States. MMWR Suppl 2016;65:50–6. https://doi.org/10.15585/mmwr.su6503a8
8. Bell BP, Damon IK, Jernigan DB, et al. Overview, control strategies, and lessons learned in the CDC response to the 2014–2016 Ebola epidemic. MMWR Suppl 2016;65(Suppl-3):4–11. https://doi.org/10.15585/mmwr.su6503a2
9. World Health Organization. Regional Office for Africa. Ebola virus disease. Democratic Republic of Congo: external situation report 60. Brazzaville, Republic of Congo: World Health Organization, Regional Office for Africa; 2019.
10. World Health Organization. Regional Office for Africa. Ebola virus disease. Democratic Republic of Congo: external situation report 45. Brazzaville, Republic of Congo: World Health Organization, Regional Office for Africa; 2019. https://apps.who.int/iris/bitstream/handle/10665/325242/SITREP_EVD_DRC_UGA_20190612-eng.pdf?ua=1

Progress Toward Rubella and Congenital Rubella Syndrome Control and Elimination — Worldwide, 2000–2018

Gavin B. Grant, MD[1]; Shalini Desai, MD[2]; Laure Dumolard, PhD[2]; Katrina Kretsinger, MD[2]; Susan E. Reef, MD[1]

Rubella is a leading cause of vaccine-preventable birth defects. Although rubella virus infection usually causes a mild febrile rash illness in children and adults, infection during pregnancy, especially during the first trimester, can result in miscarriage, fetal death, stillbirth, or a constellation of birth defects known as congenital rubella syndrome (CRS). A single dose of rubella-containing vaccine (RCV) can provide lifelong protection (*1*). In 2011, the World Health Organization (WHO) updated guidance on the use of RCV and recommended capitalizing on the accelerated measles elimination activities as an opportunity to introduce RCV (*1*). The Global Vaccine Action Plan 2011–2020 (GVAP) includes a target to achieve elimination of rubella in at least five of the six WHO regions by 2020 (*2*). This report on the progress toward rubella and CRS control and elimination updates the 2017 report (*3*), summarizing global progress toward the control and elimination of rubella and CRS from 2000 (the initiation of accelerated measles control activities) and 2012 (the initiation of accelerated rubella control activities) to 2018 (the most recent data) using WHO immunization and surveillance data. Among WHO Member States,* the number with RCV in their immunization schedules has increased from 99 (52% of 191) in 2000 to 168 (87% of 194) in 2018†; 69% of the world's infants were vaccinated against rubella in 2018. Rubella elimination has been verified in 81 (42%) countries. To make further progress to control and eliminate rubella, and to reduce the equity gap, introduction of RCV in all countries is important. Likewise, countries that have introduced RCV can achieve and maintain elimination with high vaccination coverage and surveillance for rubella and CRS. The two WHO regions that have not established an elimination goal (African [AFR] and Eastern Mediterranean [EMR]) should consider establishing a goal.§

Immunization Activities

The preferred strategy for introducing RCV into national immunization schedules is to conduct an initial vaccination campaign targeting the majority of persons who might not have been naturally exposed to rubella, usually children aged ≤14 years (*1*), a strategy that can eliminate rubella and CRS (*4*). WHO recommends that countries that introduce RCV achieve and maintain a minimum coverage of at least 80% with at least 1 dose of RCV, delivered through routine services or campaigns (*1*). Financial resources to introduce RCV are provided by governments, and Gavi, the Vaccine Alliance (Gavi) also provides substantial support for low-income and some lower-middle–income countries.

Each year, countries report immunization data to WHO and the United Nations Children's Fund using the Joint Reporting Form, which includes information on immunization schedules and the number of vaccine doses administered through routine immunization services and vaccination campaigns.¶ RCV was available in high-income countries before becoming available in lower-income countries. World Bank country income groupings were used to assess RCV introduction among countries in different income categories.**

According to Joint Reporting Form data, global coverage of infants with RCV increased from 21% in 2000 to 40% in 2012 and to 69% in 2018 (Table). In 2000, approximately half (52%, 99 of 191) of countries had introduced RCV into national immunization schedules. By the end of 2012, approximately two thirds (68%, 132 of 194) of countries were using RCV and by 2018, 168 (87%) countries had introduced RCV (Figure 1). WHO recommends that RCV be given with the first routine dose of measles-containing vaccine (MCV1) (i.e., as a combination vaccine). This recommendation has been implemented in 163 (97%) of the 168 countries that have introduced RCV; one country introduced the vaccine before the recommendations were published, and four countries administer monovalent measles vaccine at age 9 months and RCV as a combination measles-mumps-rubella vaccine at age 12 months, which is consistent with licensed use.

All countries in the Region of the Americas (AMR), the Western Pacific Region (WPR) and the European Region (EUR) have introduced RCV. In the remaining regions, RCV

* In 2000, WHO had 191 Member States worldwide; one country was added in each of three regions (African Region, European Region, and South-East Asia Region) by 2012, resulting in 194 Member States.

† One country (Indonesia) is categorized as having introduced RCV in 2018 although introduction began in 2017 and was completed by the end of 2018.

§ In 2019, the South-East Asia Region established an elimination goal, leaving two regions without an elimination goal at the time of publication.

¶ https://www.who.int/immunization/monitoring_surveillance/routine/reporting/en/.

** World Bank Gross National Income classification cut-offs per capita in USD in 2018: high income >$12,055; upper-middle income = $3,896–$12,055; lower-middle income = $996–$3,895; low income ≤$995). https://blogs.worldbank.org/opendata/new-country-classifications-income-level-2019-2020.

TABLE. Global progress toward control and elimination of rubella and congenital rubella syndrome (CRS) by World Health Organization (WHO) regions — worldwide, 2000, 2012 and 2018

	WHO region (no. of countries)						
Characteristic	**AFR (47)**	**AMR (35)**	**EMR (21)**	**EUR (53)**	**SEAR (11)**	**WPR (27)**	**Worldwide (194)***
Regional rubella/CRS target	**None**	**Elimination**	**None**	**Elimination**	**Control**	**Elimination**	**None**
No. (%) of countries verified eliminated*							
2000	N/A	N/A	N/A	N/A	N/A	N/A	N/A
2012	N/A	N/A	N/A	N/A	N/A	N/A	N/A
2018	N/A	35 (100)	3 (14)	39 (74)	6† (55)	4 (15)	81 (42)
No. (%) of countries with RCV in schedule							
2000	2 (4)	31 (89)	12 (63)	40 (77)	2 (20)	12 (44)	99 (52)
2012	3 (6)	35 (100)	14 (67)	53 (100)	5(45)	22 (81)	132 (68)
2018	27 (57)	35 (100)	16 (76)	53 (100)	10 (91)	27 (100)	168 (87)
Regional rubella vaccination coverage (%)§							
2000	0	85	23	60	3	11	21
2012	0	94	38	95	5	86	40
2018	32	90	45	95	83	94	69
No. (%) of countries reporting rubella cases							
2000	7 (15)	25 (71)	11 (52)	41 (79)	3 (30)	15 (56)	102 (53)
2012	41 (87)	35 (100)	19 (90)	47 (89)	11 (100)	23 (85)	176 (91)
2018	45 (96)	34 (97)	18 (86)	46 (87)	11 (100)	22 (81)	176 (91)
No. of reported rubella cases							
2000	865	39,228	3,122	621,039	1,165	5,475	670,894
2012	10,850	15	1,681	30,579	6,877	44,275	94,277
2018	11,787	2	1,622	798	4,533	7,264	26,006
No. (%) of countries reporting CRS cases							
2000	3 (7)	18 (51)	6 (29)	34 (65)	2 (20)	12 (44)	75 (39)
2012	20 (43)	35(100)	9 (43)	43 (81)	6 (55)	17 (63)	130 (67)
2018	19 (40)	33 (94)	13 (62)	46 (87)	10 (91)	17 (63)	138 (71)
No. of reported CRS cases							
2000	0	80	0	47	26	3	156
2012	69	3	20	62	14	134	302
2018	18	0	39	14	342	36	449

Abbreviations: AFR = African Region; AMR = Region of the Americas; EMR = Eastern Mediterranean Region; EUR = European Region; N/A = not available; RCV = rubella-containing vaccine; SEAR = South-East Asia Region; WPR = Western Pacific Region.

* In 2000, WHO had 191 Member States worldwide; one country was added in each of three regions (AFR, EUR, and SEAR) by 2012, resulting in 194 countries.

† Established regional verification commissions verify achievement of elimination in four regions (AMR, EMR, EUR, and WPR), but verify control in one (SEAR). The six countries in SEAR that have been verified as controlled are not included in the worldwide total countries eliminated.

§ Coverage estimates for rubella-containing vaccines are determined by WHO and United Nations Children's Fund Estimate National Immunization Coverage.

has been introduced in 27 (57%) of 47 countries in AFR, 16 (76%) of 21 countries in EMR, and 10 (91%) of 11 countries in the South-East Asia Region (SEAR) (Table).

The income group of countries introducing RCV has shifted over time (Figure 2). In 2000, RCV had been introduced in all 57 high-income countries but in only 13% of lower-middle–income countries and 3% of low-income countries. By 2018, 39 (85% of 46) lower-middle–income countries and 14 (45% of 31) low-income countries had introduced RCV. Fifteen countries introduced RCV in 2017 and 2018, including 14 that used financial support from Gavi (Supplementary Table, https://stacks.cdc.gov/view/cdc/81634).

Surveillance Activities

Surveillance data for rubella and CRS are also reported through the Joint Reporting Form using standard case definitions (*5*). Rubella and CRS surveillance data complement each other to provide a better picture of program progress. Rubella surveillance uses the measles surveillance system to detect cases because both illnesses cause fever and rash; however, rubella is typically milder than measles, resulting in a lower proportion of persons infected with rubella seeking health care for the illness, and therefore being detected. CRS cases are detected through separate surveillance systems, often using a few sentinel sites, which are not nationally representative (*6*).

The number of countries reporting rubella case counts, including reports of zero cases, increased from 102 (53%) in 2000 to 176 (91%) in 2012 and 2018 (Table). The number of countries reporting CRS case counts has also increased from 75 (39%) in 2000 to 130 (67%) in 2012 and to 138 (71%) in 2018. Compared with the 670,894 rubella cases reported in 2000, case counts declined by 86% in 2012 and by 96% in 2018.

FIGURE 1. Percentage of countries that have introduced rubella-containing vaccine (RCV) and the percentage with verified rubella elimination, by year — worldwide, 2000–2018



Progress Toward Elimination

Progress toward regional goals is measured by the number of countries introducing RCV and the number verified as having eliminated rubella and CRS. Rubella elimination is defined as the interruption of endemic rubella virus transmission for at least 12 months. When interruption of transmission is sustained for 36 months, an independent regional commission verifies countries as having eliminated rubella (*7*). Data on verification of elimination are from regional verification commission reports[††,§§] (*8*,*9*).

Rubella and CRS regional elimination goals have been established by AMR, EUR, and WPR; a control goal has been established by SEAR[¶¶]; AFR and EMR do not yet have a goal. The AMR commission verified the entire AMR to have eliminated rubella and CRS in 2015; verification commissions in EMR, EUR, and WPR assess rubella elimination status country-by-country. The elimination of endemic rubella has been verified in 81 countries: three of 23 (13%) in EMR, 39 of 53 (74%) in EUR, four of 27 (15%) in WPR, and 35 (100%) in AMR. In SEAR, six of 11 (55%) countries were verified to have achieved the regional control goal of a 95% reduction in cases.

Summary

What is already known about this topic?

Congenital rubella syndrome is caused by rubella virus infection of pregnant women. Since 2011, there has been an acceleration in the efforts to introduce rubella-containing vaccine using a strategy that can result in elimination.

What is added by this report?

Progress toward rubella elimination has resulted in 168 (87%) of 194 countries protecting infants with RCV and 81 (42%) eliminating rubella transmission. Equity between countries using rubella-containing vaccine has increased as lower-income countries have introduced rubella-containing vaccine.

What are the implications for public health practice?

To make further progress, it is important that the 26 remaining countries introduce rubella vaccine and the countries that have already introduced the vaccine achieve and maintain elimination.

Discussion

Progress toward rubella elimination has accelerated since 2011 with the establishment of new WHO rubella elimination goals and the availability of Gavi financial support for RCV introduction. Progress is reflected by an increase in the number of countries introducing RCV into national childhood immunization schedules and the coverage achieved, from

[††] http://www.emro.who.int/media/news/rvc-declared-bahrain-oman-iran-rubella-measles-free.html.

[§§] http://www.euro.who.int/__data/assets/pdf_file/0009/410967/8th-RVC-report-annex.pdf.

[¶¶] Rubella and CRS control is defined as a 95% reduction of rubella and CRS cases, compared with the 2010 baseline nationally and regionally.

FIGURE 2. Percentage of countries that have introduced rubella-containing vaccine, by World Bank income group* and year — worldwide, 2000–2018



* Gross National Income per capita in USD in 2018: high income >$12,055; upper-middle income = $3,896–$12,055; lower-middle income = $996–$3,895; low income ≤$995). https://blogs.worldbank.org/opendata/new-country-classifications-income-level-2019-2020.

99 countries in 2000 (21% global RCV coverage) to 132 in 2012 (40% coverage) and 168 in 2018 (69% coverage). The equity gap in access to RCV among countries has narrowed as more middle-income and low-income countries have introduced RCV, in part with funding from Gavi to support activities required for introduction; however, inequities remain among countries and at subnational levels.

Providing policy-makers in countries that have not yet introduced RCV with data on the impact of the investment to introduce RCV can help them determine whether their country should introduce RCV. The decision-making process benefits from 1) evaluation of the impact of RCV introduction on CRS; 2) consideration of the opportunities offered by accelerated measles elimination activities (e.g., campaigns); and 3) evaluation of the long-term sustainability of financing for RCV along with other vaccines. It is important that all countries that have not reached >95% measles-containing vaccine coverage (the level needed to achieve measles elimination) continue to improve population immunity with high-coverage routine services and campaigns and, by doing so, also eliminate rubella. In addition, countries that had introduced RCV in selected populations (usually females only) to control CRS, have large immunity gaps (usually in men) and might need to develop plans to identify and protect susceptible populations to achieve elimination. Research and innovation will help improve surveillance, target programmatic activities more effectively, and develop new vaccination delivery systems to help further accelerate progress toward rubella and measles elimination (*10*).

The findings in this report are subject to at least two limitations. First, improvements in the accuracy and reliability of available surveillance and immunization data are needed to better identify immunity gaps, to focus immunization-strengthening activities, and to demonstrate the interruption of rubella virus transmission. Second, the impact of recent RCV introductions (e.g., two large countries in SEAR introducing RCV in 2018) might not be fully reflected in the available surveillance data.

Increases in the number of countries introducing RCV into national immunization schedules, in global RCV coverage, and in the number of countries verified as having eliminated endemic rubella transmission demonstrate the progress toward control and ultimately the elimination of rubella.

The countries verified as having eliminated rubella serve as important examples and provide valuable lessons for other countries. Countries in all income groups can eliminate rubella by introducing RCV, strengthening surveillance, and improving immunization service delivery.

Corresponding author: Gavin Grant, gig9@cdc.gov, 404-639-8806.

[1]Global Immunization Division, Center for Global Health, CDC; [2]Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

References

1. World Health Organization. Rubella vaccines: WHO position paper. Wkly Epidemiol Rec 2011;86:301–16.
2. World Health Organization. Global vaccine action plan. Geneva, Switzerland: World Health Organization; 2012. https://apps.who.int/iris/bitstream/handle/10665/78141/9789241504980_eng.pdf;jsessionid=1FCD8BDCCCAACC8E89F9BCB89D15C5B8?sequence=
3. Grant GB, Reef SE, Patel M, Knapp JK, Dabbagh A. Progress in rubella and congenital rubella syndrome control and elimination—worldwide 2000–2016. MMWR Morb Mortal Wkly Rep 2017;66:1256–60. https://doi.org/10.15585/mmwr.mm6645a4
4. Castillo-Solórzano C, Marsigli C, Bravo-Alcántara P, et al. Elimination of rubella and congenital rubella syndrome in the Americas. J Infect Dis 2011;204(Suppl 2):S571–8. https://doi.org/10.1093/infdis/jir472
5. World Health Organization. Surveillance standards for vaccine-preventable diseases. Geneva, Switzerland: World Health Organization; 2018. https://www.who.int/immunization/monitoring_surveillance/burden/vpd/standards/en/
6. Patel MK, Gibson R, Cohen A, Dumolard L, Gacic-Dobo M. Global landscape of measles and rubella surveillance. Vaccine 2018;36:7385–92. https://doi.org/10.1016/j.vaccine.2018.10.007
7. World Health Organization. Guidance for evaluating progress towards elimination of measles and rubella. Wkly Epidemiol Rec 2018;93:544–52. https://apps.who.int/iris/handle/10665/275394
8. World Health Organization, Regional Office for Western Pacific. Seventh annual meeting of the Regional Verification Commission for Measles and Rubella Elimination in the Western Pacific. Kuala Lumpur, Malaysia: World Health Organization, Regional Office for Western Pacific; 2018. https://iris.wpro.who.int/handle/10665.1/14333
9. World Health Organization, Regional Office for South-East Asia. Third meeting of the South-East Asia Regional Verification Commission for Measles Elimination and Rubella/Congenital Rubella Syndrome Control. New Delhi, India: World Health Organization, Regional Office for South-East Asia; 2018. https://apps.who.int/iris/handle/10665/277455
10. Grant GB, Masresha BG, Moss WJ, et al. Accelerating measles and rubella elimination through research and innovation—findings from the Measles & Rubella Initiative research prioritization process, 2016. Vaccine 2019;37:5754–61. https://doi.org/10.1016/j.vaccine.2019.01.081

Morbidity and Mortality Weekly Report

Characteristics of a Multistate Outbreak of Lung Injury Associated with E-cigarette Use, or Vaping — United States, 2019

Cria G. Perrine, PhD[1]; Cassandra M. Pickens, PhD[2]; Tegan K. Boehmer, PhD[3]; Brian A. King, PhD[1]; Christopher M. Jones, DrPH[2]; Carla L. DeSisto, PhD[1,4]; Lindsey M. Duca, PhD[1,4]; Akaki Lekiachvili, MD[1]; Brandon Kenemer, MPH[1]; Mays Shamout, MD[1,4]; Michael G. Landen, MD[5]; Ruth Lynfield, MD[6]; Isaac Ghinai, MBBS[4,7]; Amy Heinzerling, MD[4,8]; Nathaniel Lewis, PhD[4,9]; Ian W. Pray, PhD[4,10]; Lauren J. Tanz, ScD[4,11]; Anita Patel, PharmD[12]; Peter A. Briss, MD[1]; Lung Injury Response Epidemiology/Surveillance Group

On September 27, 2019, this report was posted as an MMWR *Early Release on the* MMWR *website (https://www.cdc.gov/mmwr).*

Electronic cigarettes (e-cigarettes), also called vapes, e-hookas, vape pens, tank systems, mods, and electronic nicotine delivery systems (ENDS), are electronic devices that produce an aerosol by heating a liquid typically containing nicotine, flavorings, and other additives; users inhale this aerosol into their lungs (*1*). E-cigarettes also can be used to deliver tetrahydrocannabinol (THC), the principal psychoactive component of cannabis (*1*). Use of e-cigarettes is commonly called vaping. Lung injury associated with e-cigarette use, or vaping, has recently been reported in most states (*2–4*). CDC, the Food and Drug Administration (FDA), state and local health departments, and others are investigating this outbreak. This report provides data on patterns of the outbreak and characteristics of patients, including sex, age, and selected substances used in e-cigarette, or vaping, products reported to CDC as part of this ongoing multistate investigation. As of September 24, 2019, 46 state health departments and one territorial health department had reported 805 patients with cases of lung injury associated with use of e-cigarette, or vaping, products to CDC. Sixty-nine percent of patients were males, and the median age was 23 years (range = 13–72 years). To date, 12 deaths have been confirmed in 10 states. Among 514 patients with information on substances used in e-cigarettes, or vaping products, in the 30 days preceding symptom onset, 76.9% reported using THC-containing products, and 56.8% reported using nicotine-containing products; 36.0% reported exclusive use of THC-containing products, and 16.0% reported exclusive use of nicotine-containing products. The specific chemical exposure(s) causing the outbreak is currently unknown. While this investigation is ongoing, CDC recommends that persons consider refraining from using e-cigarette, or vaping, products, particularly those containing THC. CDC will continue to work in collaboration with FDA and state and local partners to investigate cases and advise and alert the public on the investigation as additional information becomes available.

State health departments, the Council of State and Territorial Epidemiologists (CSTE), and CDC have developed definitions for confirmed and probable cases* and medical chart abstraction and case interview forms. The case definition, forms, and instructions for reporting cases were disseminated to all state health departments in late August 2019. Patients with cases of lung injury associated with e-cigarette use, or vaping, had 1) a history of e-cigarette use, vaping, or dabbing (vaping concentrated marijuana) within 90 days before symptom onset; 2) imaging studies showing lung injury; 3) absence of evidence of infection (confirmed cases) or infection not thought to be the sole cause of the lung injury or infectious disease testing not performed (probable cases); and 4) absence of alternative plausible diagnoses. Most states are reporting case counts to CDC as case status is determined; however, it can take up to several weeks to complete and submit information from medical chart abstraction and interviews. Additional time might be required after the information is submitted to CDC to clean and standardize data submitted in different formats. This report summarizes patterns of the lung injury outbreak and characteristics of cases reported to CDC, including demographic characteristics and selected substances used by patients.†

As of September 24, 2019, 805 cases of lung injury from 46 states and one territory had been reported to CDC (Figure 1). Among the 805 cases reported, basic patient data (i.e., demographics and dates of symptom onset and hospitalization) were received for 771 (96%) patients. Ninety-one percent of patients were hospitalized. Median duration between symptom onset and hospitalization was 6 days (range = 0–158 days) (Figure 2). Although some cases occurred during April–June 2019, the number of cases began increasing in early July. The decline in reporting of onset dates and hospitalizations in the most recent 3–4 weeks is the result, in part, of a lag in reporting; there is no evidence that occurrence of lung injury cases is declining.

Sixty-nine percent of patients were male (Table). Median age was 23 years (range = 13–72 years); 61.9% were aged 18–34 years, and 16.2% were aged <18 years. Among the 12 deaths reported

* https://www.cdc.gov/tobacco/basic_information/e-cigarettes/assets/2019-Lung-Injury-Surveillance-Case-Definition-508.pdf.

† CDC determined the intent of this project to be public health practice for disease and injury control; thus, the activity is not research involving human subjects and Institutional Review Board approval was not required (OMB No. 0920–1011).

to CDC, 58% occurred in men, and the median age was 50 years (range = 27–71 years). Among a subset of 514 patients (63.8%) for whom information on substances used in e-cigarettes, or vaping, products was available, 395 (76.9%) reported using THC-containing products, and 292 (56.8%) reported using nicotine-containing products in the 30 days preceding symptom onset; 210 patients (40.9%) reported using both THC-containing and nicotine-containing products, 185 (36.0%) reported exclusive use of THC-containing products, and 82 (16.0%) reported exclusive use of nicotine-containing products.

Discussion

E-cigarettes were introduced to the U.S. market in 2007 (*1*). In 2018, 20.8% of high school students reported current e-cigarette use (*5*). E-cigarette use is markedly lower among U.S. adults than among youths; in 2018, only 3.2% of adults currently used e-cigarettes, with higher prevalences among persons aged 18–24 years (7.6%) and 25–34 years (5.4%) than among older age groups (*6*). Approximately three fourths of patients in this investigation were aged <35 years. In the general U.S. adult population, current e-cigarette use is slightly higher among males than females for both adults and youths (*6*); in the present investigation, approximately seven in 10 cases occurred in males. In this investigation, 62% of patients were aged 18–34 years; this is consistent with the age group with highest reported prevalence of marijuana use in the preceding 30 days in the United States (*7*).

THC-containing and nicotine-containing products were the most commonly reported substances used in e-cigarettes, or vaping products, by patients. Specific data on use of THC in e-cigarettes, or vaping products, in the general population is limited; among U.S. middle and high school students in 2016 who had ever used an e-cigarette, 30.6% reported using THC in an e-cigarette (33.3% among males and 27.2% among females) (*8*). Among adults who reported using marijuana in 2014, 9.9% reported consuming it via a vaporizer or other electronic device (11.5% among men and 7.8% among women) (*9*). In a recent study of college students, approximately 75% of those who had used substances other than nicotine in e-cigarettes reported using marijuana or THC-containing products in an e-cigarette (*10*). Because information about substance use in this investigation was self-reported, the information is not available for some cases because of the time required for completing and reporting patient interviews, inability to conduct interviews (e.g., patient refusal, loss to follow-up, persons who were too ill or died before they could be interviewed) and missing data for certain variables (e.g., patient refusal to answer certain questions). In addition, patients might not always know what substances they use or might be hesitant to reveal use of substances that are not legal in their state.

FIGURE 1. Number of cases of lung injury associated with e-cigarette use, or vaping (n = 805) — United States, including two territories, 2019



Abbreviations: DC = District of Columbia, PR = Puerto Rico; VI = U.S. Virgin Islands.
* As of September 24, 2019, 1–9 cases had been reported by 23 states and one territory; 10–29 cases had been reported by 14 states; 30–49 cases had been reported by five states; 50–99 cases had been reported by four states, and 0 cases had been reported by four states and DC. Additional cases being investigated are not reflected on this map.

Continued monitoring of patient case counts and characteristics, as well as substances used with e-cigarette, or vaping, products, is critical to informing the ongoing investigation and helping to identify the cause. CDC and state health departments continue to collect and analyze epidemiologic data to better understand what types of devices and products patients are using (e.g., cartridges and e-liquids), the source of products or location where they were obtained, and the patterns (e.g., duration and frequency) of specific product use. Given the vast number of chemicals used in e-cigarette, or vaping, products, it is important to link epidemiologic data with findings from laboratory analyses of products and clinical specimens from patients. Federal, state, and private laboratories are working to collect and analyze products obtained from patients with lung injury associated with e-cigarette use, or vaping. In addition, CDC, clinical, and public health laboratories are collecting clinical specimens for future targeted analyses of substances identified in product samples.

The specific chemical exposure(s) causing this outbreak is unknown at this time. National data to date show that most lung injury patients with data on substance use report using THC-containing products with or without nicotine-containing products, although some patients report using only nicotine-containing products. While this investigation is ongoing, CDC recommends that persons consider refraining from using e-cigarette, or vaping, products, particularly those containing THC. Persons who continue to use e-cigarettes

FIGURE 2. Dates of symptom onset (n = 590) and hospital admission (n = 674) among patients with lung injury associated with e-cigarette use, or vaping — United States, March 31–September 21, 2019



or vaping products should carefully monitor themselves and seek medical attention immediately if they have symptoms consistent with those described in this outbreak.[§]

Regardless of the investigation, e-cigarettes, or vaping products, should never be used by youths, young adults, pregnant women, or by adults who do not currently use tobacco products (*2*). Adults who use e-cigarettes because they have quit smoking should not return to smoking combustible cigarettes. In addition, persons who use e-cigarettes or vaping products should not get them from informal sources or off the street and should not modify e-cigarette, or vaping, devices or add any substances that are not intended by the manufacturer. Both THC-containing and nicotine-containing e-cigarette, or vaping, products purchased legally within states might also contain harmful substances (*1*); it is difficult for consumers to know what is in these products, and full ingredient lists are typically not available. THC use has been associated with a wide range of health effects, particularly with prolonged heavy use.[¶] The best way to avoid potentially harmful effects is to not use THC, including through e-cigarette, or vaping, devices. Persons with marijuana use disorder should seek evidence-based treatment by a health care provider.

This investigation is ongoing. CDC will continue to work in collaboration with FDA and state and local partners to investigate cases and advise and alert the public on the investigation as additional information becomes available.

[§] https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease/need-to-know/index.html.

[¶] http://nationalacademies.org/hmd/reports/2017/health-effects-of-cannabis-and-cannabinoids.aspx.

Summary

What is already known about this topic?

Lung injury associated with e-cigarette use, or vaping, has recently been reported in most states. CDC, the Food and Drug Administration, and others are investigating this outbreak.

What is added by this report?

Among 805 cases reported as of September 24, 2019, 69% were in males; 62% of patients were aged 18–34 years. Among patients with data on substances used in e-cigarettes, or vaping products, tetrahydrocannabinol (THC)-containing product use was reported by 76.9% (36.0% reported exclusive THC-product use); 56.8% reported nicotine-containing product use (16.0% reported exclusive nicotine-product use).

What are the implications for public health practice?

The cause of the outbreak is unknown. While this investigation is ongoing, CDC recommends that persons consider refraining from using e-cigarette, or vaping, products, particularly those containing THC.

Corresponding author: Cria G. Perrine; cperrine@cdc.gov.

[1]National Center for Chronic Disease Prevention and Health Promotion, CDC; [2]National Center for Injury Prevention and Control, CDC; [3]National Center for Environmental Health, CDC; [4]Epidemic Intelligence Service, CDC; [5]New Mexico Department of Health; [6]Minnesota Department of Health; [7]Illinois Department of Public Health; [8]California Department of Public Health; [9]Utah Department of Health; [10]Wisconsin Department of Health Services; [11]North Carolina Department of Health and Human Services; [12]National Center for Immunization and Respiratory Diseases, CDC.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

TABLE. Number of patients with lung injury associated with e-cigarette use, or vaping (n = 771), by demographic and substance use characteristics — United States, 2019

Characteristic	No. (%)
Demographic (n = 771)*	
Sex	
Male	531 (68.9)
Female	234 (30.4)
Missing	6 (0.8)
Age group (yrs)	
<18	125 (16.2)
18–24	293 (38.0)
25–34	184 (23.9)
35–44	93 (12.1)
≥45	42 (5.5)
Missing	34 (4.4)
Substances used in e-cigarette, or vaping, products (n = 514)†	
THC-containing products	
Yes	395 (76.9)
No	96 (18.7)
Unknown/Missing	23 (4.5)
Nicotine-containing products	
Yes	292 (56.8)
No	173(33.7)
Unknown/Missing	49 (9.5)
Cannabidiol (CBD)	
Yes	89 (17.3)
No	265 (51.6)
Unknown/Missing	160 (31.1)
Synthetic cannabinoids	
Yes	4 (0.8)
No	289 (56.2)
Unknown/Missing	221 (43.0)
Flavored e-liquids§	
Yes	102 (19.8)
No	132 (25.7)
Unknown/Missing	280 (54.5)

Abbreviation: THC = tetrahydrocannabinol.

* Patients for whom basic demographic information was submitted to CDC.

† Patients for whom information was available on use of either nicotine-containing or THC-containing substances.

§ Flavored products that contain water, food-grade flavoring, propylene glycol, vegetable glycerin, nicotine, THC, or CBD.

References

1. US Department of Health and Human Services. E-cigarette use among youth and young adults. A report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, CDC; 2016. https://e-cigarettes.surgeongeneral.gov/documents/2016_sgr_full_report_non-508.pdf
2. Schier JG, Meiman JG, Layden J, et al.; CDC 2019 Lung Injury Response Group. Severe pulmonary disease associated with electronic-cigarette–product use—interim guidance. MMWR Morb Mortal Wkly Rep 2019;68:787–90. https://doi.org/10.15585/mmwr.mm6836e2
3. Layden JE, Ghinai I, Pray I, et al. Pulmonary illness related to e-cigarette use in Illinois and Wisconsin—preliminary report. N Engl J Med 2019;NEJMoa1911614. https://doi.org/10.1056/NEJMoa1911614
4. Davidson K, Brancato A, Heetderks P, et al. Outbreak of e-cigarette associated acute lipoid pneumonia—North Carolina, July–August 2019. MMWR Morb Mortal Wkly Rep 2019;68:784–6. https://doi.org/10.15585/mmwr.mm6836e1
5. Gentzke AS, Creamer M, Cullen KA, et al. Vital signs: tobacco product use among middle and high school students—United States, 2011–2018. MMWR Morb Mortal Wkly Rep 2019;68:157–64. https://doi.org/10.15585/mmwr.mm6806e1
6. Dai H, Leventhal AM. Prevalence of e-cigarette use among adults in the United States, 2014–2018. JAMA 2019. https://doi.org/10.1001/jama.2019.15331
7. Substance Abuse and Mental Health Services Administration. Results from the 2018 National Survey on Drug Use and Health: detailed tables. Washington DC: Substance Abuse and Mental Health Services Administration; 2019. https://www.samhsa.gov/data/nsduh/reports-detailed-tables-2018-NSDUH
8. Trivers KF, Phillips E, Gentzke AS, Tynan MA, Neff LJ. Prevalence of cannabis use in electronic cigarettes among US youth. JAMA Pediatr 2018;172:1097–9.
9. Schauer GL, King BA, Bunnell RE, Promoff G, McAfee TA. Toking, vaping, and eating for health or fun: marijuana use patterns in adults, U.S., 2014. Am J Prev Med 2016;50:1–8. https://doi.org/10.1016/j.amepre.2015.05.027
10. Kenne DR, Fischbein RL, Tan AS, Banks M. The use of substances other than nicotine in electronic cigarettes among college students. Subst Abuse 2017;11:1178221817733736. https://doi.org/10.1177/1178221817733736

Lung Injury Response Epidemiology/Surveillance Group

Jennifer Adjemian, Center for Surveillance, Epidemiology, and Laboratory Services, CDC; Minal Amin, National Center for Immunization and Respiratory Diseases, CDC; Jose Aponte, Center for Surveillance, Epidemiology, and Laboratory Services, CDC; Vaughn Barry, Epidemic Intelligence Service, National Center for Injury Prevention and Control, CDC; Diane Browning, Northrop Grumman; Jordan Cates, Epidemic Intelligence Service, National Center for Immunization and Respiratory Diseases, CDC; Gyan Chandra, National Center for Chronic Disease Prevention and Health Promotion, CDC; Karen Chang, Epidemic Intelligence Service, National Center for Chronic Disease Prevention and Health Promotion, CDC; Katelyn Chiang, National Center for Chronic Disease Prevention and Health Promotion, CDC; Jennifer Chevinsky, Epidemic Intelligence Service, National Center for Chronic Disease Prevention and Health Promotion, CDC; Augustina Delaney, G^{2}S Corporation; Angela Dunn, Utah Department of Health; Molly Evans, National Center for Injury Prevention and Control, CDC; Victoria Fields, Epidemic Intelligence Service, National Center on Birth Defects and Developmental Disabilities, CDC; Aaron Fleischauer, North Carolina Department of Health and Human Services, Center for Preparedness and Response, CDC; Macarena Garcia, Center for Surveillance, Epidemiology, and Laboratory Services, CDC; Caitlin Green, National Center on Birth Defects and Developmental Disabilities, CDC; Arianna Hanchey, National Center for Environmental Health, CDC; Kathleen Hartnett, Center for Surveillance, Epidemiology, and Laboratory Services, CDC; Brooke Hoots, National Center for Injury Prevention and Control, CDC; Asad Islam, Center for Surveillance, Epidemiology, and Laboratory Services, CDC; Charlotte Kaboré, National Center for Chronic Disease Prevention and Health Promotion, CDC; Vikram Krishnasamy, National Center for Injury Prevention and Control, CDC; Mohammed Lamtahri, Center for Surveillance, Epidemiology, and Laboratory Services, CDC; Jennifer Layden, Illinois Department of Public Health; Dana Meany-Delman, National Center on Birth Defects and Developmental Disabilities; Jonathan Meiman, Wisconsin Department of Health Services; Christina Mikosz, National Center for Injury Prevention and Control, CDC; Maureen Miller, Epidemic Intelligence Service, National Center for Chronic Disease Prevention and Health Promotion, CDC; Yousra Mohamoud, National Center for Chronic Disease Prevention and Health Promotion, CDC; Erin Moritz, National Center for Environmental Health, CDC; Varsha Neelam, National Center on Birth Defects and Developmental Disabilities, CDC; David Nitschke, Center for Surveillance, Epidemiology, and Laboratory Services, CDC; Kevin O'Laughlin, Epidemic Intelligence Service, National Center for Emerging and Zoonotic Infectious Diseases, CDC; Samantha Olson, G^{2}S Corporation; Tia Rogers, Epidemic Intelligence Service, National Center for Injury Prevention and Control, CDC; Nicki Roth, Eagle Medical Services; Phil Salvatore, Epidemic Intelligence Service, National Center for Injury Prevention and Control, CDC; Alana Vivolo-Kantor, National Center for Injury Prevention and Control, CDC; Angela Werner, National Center for Environmental Health, CDC; Jason Wilken, California Department of Public Health, Center for Preparedness and Response, CDC; Council of State and Territorial Epidemiologist Vaping-Associated Pulmonary Injury Task Force.

E-cigarette Product Use, or Vaping, Among Persons with Associated Lung Injury — Illinois and Wisconsin, April–September 2019

Isaac Ghinai[1,2*]; Ian W. Pray[2,3*]; Livia Navon[1,4]; Kevin O'Laughlin[2]; Lori Saathoff-Huber[1]; Brooke Hoots[5]; Anne Kimball[2]; Mark W. Tenforde[2]; Jennifer R. Chevinsky[2]; Mark Layer[6,7]; Ngozi Ezike[1]; Jonathan Meiman[3]; Jennifer E. Layden[1]

On September 27, 2019, this report was posted as an MMWR *Early Release on the* MMWR *website (https://www.cdc.gov/mmwr).*

In July 2019, the Illinois Department of Public Health and the Wisconsin Department of Health Services launched a coordinated epidemiologic investigation after receiving reports of several cases of lung injury in previously healthy persons who reported electronic cigarette (e-cigarette) use, or vaping (*1*). This report describes features of e-cigarette product use by patients in Illinois and Wisconsin. Detailed patient interviews were conducted by telephone, in person, or via the Internet with 86 (68%) of 127 patients. Overall, 75 (87%) of 86 interviewed patients reported using e-cigarette products containing tetrahydrocannabinol (THC), and 61 (71%) reported using nicotine-containing products. Numerous products and brand names were identified by patients. Nearly all (96%) THC-containing products reported were packaged, prefilled cartridges, and 89% were primarily acquired from informal sources (e.g., friends, family members, illicit dealers, or off the street). In contrast, 77% of nicotine-containing products were sold as prefilled cartridges, and 83% were obtained from commercial vendors. The precise source of this outbreak is currently unknown (*2*); however, the predominant use of prefilled THC-containing cartridges among patients with lung injury associated with e-cigarette use suggests that they play an important role. While this investigation is ongoing, CDC recommends that persons consider refraining from using e-cigarette, or vaping, products, particularly those containing THC. Given the diversity of products reported and frequency of patients using both THC- and nicotine-containing e-cigarette products, additional methods such as product testing and traceback could help identify the specific cause of this outbreak.

During July–September 2019, possible cases of lung injury associated with e-cigarette use in Illinois and Wisconsin were investigated to determine symptoms, exposures, and medical care history related to the outbreak. Patients were classified as having confirmed or probable cases of lung injury associated with e-cigarette use according to CDC's interim outbreak case definitions (*3*). Interviews were conducted with patients or a proxy using a structured and scripted questionnaire that was developed jointly between Illinois and Wisconsin with guidance from CDC. The questionnaire asked detailed questions about e-cigarette use, including the names of e-cigarette, or vaping, products and devices, frequency of use, and product sources in the 3 months preceding illness onset. Most interviews were conducted by state or local health department staff members or in person by health care facility staff members during a patient's hospitalization; a small number of patients completed the same survey online. In total, 86 (68%) interviews were completed among the 127 confirmed and probable patients that had been identified in Illinois (75) and Wisconsin (52) as of September 20, 2019.

Among the 86 confirmed and probable patients that were interviewed, including 48 from Illinois and 38 from Wisconsin, 68 (79%) were male, and the median age was 21 years (range = 15–53 years) (Table 1). Hospitalization dates among patients were similar in Illinois and Wisconsin, ranging from April 24 to September 19, 2019, and closely reflected the national outbreak (*2*). Illinois cases predominantly occurred in the northeast region of the state (in Chicago and the surrounding counties, close to the Wisconsin border) but have since been reported in other regions of the state. Most Wisconsin cases were initially clustered in the southeastern region of the state but have since been reported throughout western and central Wisconsin as well.

Among the 86 interviewed patients, 75 (87%) reported using e-cigarette products containing THC, the principal psychoactive component of cannabis, during the 3 months preceding illness; 61 (71%) reported using nicotine-containing products; 50 (58%) reported using both THC- and nicotine-containing products. Twenty-five (29%) patients reported exclusive use of THC-containing products, whereas 11 (13%) reported exclusive use of nicotine-containing products (Table 2). Demographic characteristics of patients were similar among those who reported exclusive use of THC-containing products, exclusive use of nicotine-containing products, or use of both types of products (Table 1).

The chemical contents of reported THC-containing products are unknown. However, urinary THC screens were obtained for 32 patients who reported using THC-containing products, 29 (91%) of which were positive for THC; two patients who did not report using THC-containing e-cigarette products, out of four tested, also had positive urinary THC screens; one of these patients reported smoking combustible marijuana. Urinary THC levels for four patients who reported using THC-containing products exceeded 400 ng/ml, indicating intensive

*These authors contributed equally.

TABLE 1. Patient characteristics by type of electronic cigarette, or vaping, product used in the 3 months prior to illness onset — Illinois and Wisconsin, 2019

Characteristic	n/N (%)			
	THC-containing products only (N = 25)	Nicotine-containing products only (N = 11)	Both THC- and nicotine-containing products (N = 50)	Total (N = 86)
Age group (yrs)				
<18	5/25 (20)	3/11 (27)	11/50 (22)	**19/86 (22)**
18–24	7/25 (28)	4/11 (36)	27/50 (54)	**38/86 (44)**
25–34	7/25 (28)	3/11 (27)	9/50 (18)	**19/86 (22)**
≥35	6/25 (24)	1/11 (9)	3/50 (6)	**10/86 (12)**
Gender				
Male	22/25 (88)	8/11 (73)	38/50 (76)	**68/86 (79)**
Female	3/25 (12)	3/11 (27)	12/50 (24)	**18/86 (21)**
Race/Ethnicity*				
White, non-Hispanic†	13/22 (59)	8/11 (73)	39/46 (85)	**60/79 (76)**
Black, non-Hispanic†	2/22 (9)	2/11 (18)	3/46 (7)	**7/79 (9)**
Other, non-Hispanic†	0/22 (0)	0/11 (0)	2/46 (4)	**2/79 (3)**
Hispanic†	7/22 (32)	1/11 (9)	2/46 (4)	**10/79 (13)**
Other characteristics				
Admitted to ICU§	12/19 (63)	5/8 (63)	25/44 (57)	**42/71 (59)**
Smoked combustible marijuana¶	12/24 (50)	5/11 (45)	26/48 (54)	**43/83 (52)**
Smoked combustible tobacco¶	3/24 (13)	4/11 (36)	13/48 (27)	**20/83 (24)**

Abbreviations: ICU = intensive care unit; THC = tetrahydrocannabinol.
* Information missing for seven patients.
† Blacks, whites, and persons of other races were non-Hispanic; Hispanic persons could be of any race.
§ Information missing for 15 patients.
¶ Information missing for three patients.

TABLE 2. Electronic cigarette (e-cigarette), or vaping, product use behaviors in the 3 months prior to illness onset in patients with lung injury associated with e-cigarette use — Illinois and Wisconsin, 2019

Product use and behaviors	No. (%)		
	Illinois (n = 48)	Wisconsin (n = 38)	Total (N = 86)
THC-containing product use			
Any use	39 (81)	36 (95)	**75 (87)**
Exclusive use	13 (27)	12 (32)	**25 (29)**
Dank Vapes use	33 (73)	24 (63)	**57 (66)**
Nicotine-containing product use			
Any use	35 (73)	26 (68)	**61 (71)**
Exclusive use	9 (19)	2 (5)	**11 (13)**
Both THC- and nicotine-containing product use	26 (54)	24 (63)	**50 (58)**
At least daily use of e-cigarette products*			
THC-containing products	29 (60)	20 (53)	**49 (57)**
Nicotine-containing products	27 (56)	18 (47)	**45 (52)**
Devices used with e-cigarette products†			
Device designed for prefilled cartridge use	43 (91)	35 (92)	**78 (92)**
Tank designed to be filled with product	7 (15)	11 (29)	**18 (21)**
Dab rig or a dab pen	7 (15)	7 (18)	**14 (16)**
No. of e-cigarette product brands reported per product type user†			
THC brands per THC user,§ mean (range)	2.1 (1–7)	2.1 (1–7)	**2.1 (1–7)**
Nicotine brands per nicotine user,¶ mean (range)	1.3 (1–3)	1.3 (1–4)	**1.3 (1–4)**
Packaging of e-cigarette products used			
No./total of THC products (%) that were packaged, prefilled cartridges	69/72 (96)	80/83 (96)	**149/155 (96)**
No./total of nicotine products (%) that were packaged, prefilled cartridges	32/35 (91)	29/44 (66)	**61/79 (77)**

Abbreviation: THC = tetrahydrocannabinol.
* The denominator used here is all patients, not just those who reported using THC- or nicotine-containing products.
† Patients could report using more than one type of device or product, thus the percentage totals sum to >100%.
§ Patients were counted as THC users if they reported use of at least one THC-containing e-cigarette product in the past 3 months.
¶ Patients were counted as nicotine users if they reported use of at least one nicotine-containing e-cigarette product in the past 3 months.

use of THC or THC-containing products (*4,5*). In Wisconsin, eight patients initially denied using THC-containing products in interviews, but five (63%) were later found to have used THC through review of medical charts, reinterview, or cross-referencing with friends who were also interviewed as patients.

Among the 86 interviewed patients, 234 unique e-cigarette, or vaping, products labeled with 87 different brand names were reported. Nicotine-containing product users reported a mean of 1.3 different nicotine brands (range = 1–4), and THC-containing product users reported a mean of 2.1 different THC brands (range = 1–7). Among 155 THC-containing products reported, nearly all (149, 96%) were packaged, prefilled cartridges, whereas 61 (77%) of 79 nicotine-containing products were sold as prefilled cartridges or "pods." No patients reported adding other ingredients to the e-cigarette products they used. Although no single brand name was reported by all patients, a prefilled THC cartridge sold under the brand name Dank Vapes was reported by 57 (66%) patients (Figure). In Wisconsin, two groups of friends (two patients in one group and three in the second group) who became ill after using THC-containing cartridges specifically reported sharing Dank Vapes cartridges. Dank Vapes was the only e-cigarette product reported by one of the patients.

Among 112 THC-containing products for which the source was reported, 100 (89%) were acquired from informal sources (e.g., friends, family, school, dealers, or off the street). The remaining 12 were bought at an out-of-state cannabis dispensary (six), online (five), or from a vape or tobacco shop (one). In contrast, among 81 nicotine-containing products, 40 (49%) were obtained from a vape or tobacco shop, 22 (27%) from gas stations or convenience stores, 14 (17%) from friends or family, and five (6%) online.

A variety of e-cigarette and vaping device types (*6*) were used by patients to aerosolize THC- or nicotine-containing products. Overall, 78 (92%) of 85 patients reported using a device designed to aerosolize prefilled cartridges or pods. Within this category of vaping devices, some were closed-pod systems (also known as "mods") designed for use with proprietary nicotine-containing products (e.g., JUUL); however, most were universal "vape pens" that are adaptable to the prefilled THC cartridges reported by many patients. Use of devices with a tank designed to be filled with nicotine-containing liquid or THC oil was reported by 18 (21%) patients, and 14 (16%) reported aerosolizing THC concentrates, known as waxes or "dabs," using either a "dab rig" or a "dab pen" device.†

Patients reported frequent daily use of e-cigarette products; among 75 users of THC-containing products, 49 (65%)

† Dabbing is a process that allows the user to inhale a high concentration of THC by vaporizing extracts of a concentrate that has been placed on a hot surface.

FIGURE. Frequently reported brand names of tetrahydrocannabinol (THC)- and nicotine-containing electronic cigarette (e-cigarette), or vaping, products*,†,§ reported by patients with lung injury¶ — Illinois and Wisconsin, 2019



* Two brands of cannabidiol are not shown (each brand reported by one patient).
† 30 other THC-containing brands (including three brands of THC wax for "dabbing") were only reported by one patient each.
§ 22 other nicotine-containing brands were only reported by one patient each.
¶ Data are presented from interviews conducted with 86 of 127 patients with lung injury associated with e-cigarette use, or vaping.

Summary

What is already known about this topic?

An outbreak of lung injury of unknown source associated with electronic cigarette (e-cigarette) use is ongoing in the United States.

What is added by this report?

Interviews about e-cigarette use were completed with 86 patients in Illinois and Wisconsin. Use of tetrahydrocannabinol (THC)-containing e-cigarette products, the majority of which were prefilled cartridges obtained from informal sources, was reported by 87% of patients during the 3 months preceding illness.

What are the implications for public health practice?

The cause of this outbreak is unknown but might be related to prefilled THC cartridges. While this investigation is ongoing, CDC recommends that persons consider refraining from using e-cigarette, or vaping, products, particularly those containing THC. Additional information from product testing and traceback could help determine the source of the outbreak and prevent future illnesses.

reported using these products at least daily, and 45 (74%) of 61 nicotine-containing product users reported at least daily use of these products. Where more detailed information on frequency of use was provided, 21 (41%) of 51 THC-containing product users and 30 (65%) of 46 nicotine-containing product users reported use of at least one such product five or more times a day. In addition to e-cigarette products, among 83 patients who provided information on combustible product use, 43 (52%) reported smoking combustible marijuana, and 20 (24%) reported smoking combustible tobacco.

Only four (5%) of 86 interviewed patients reported prescription drug misuse or illicit drug use other than THC. Two patients reported using LSD, one reported misusing dextroamphetamine-amphetamine (Adderall), and one reported misusing oxycodone. Urinary toxicology screens were positive for substances other than THC (and for other substances that could not be explained by the medical treatment these patients had received) in six of 31 patients, including two patients who tested positive for benzodiazepines and opioids, one for benzodiazepines alone, one for opioids alone, one for amphetamines, and one for unspecified narcotics.

Discussion

In this series of in-depth interviews with 86 e-cigarette– or vaping-associated lung injury patients in Illinois and Wisconsin during July–September 2019, patients reported a wide range of e-cigarette products; however, the vast majority reported using illicit THC-containing products sold as prefilled cartridges and obtained from informal sources. Although no single brand or product was definitively identified, a high percentage of patients reported using Dank Vapes cartridges. Dank Vapes appears to be the most prominent in a class of largely counterfeit brands, with common packaging that is easily available online and that is used by distributors to market THC-containing cartridges with no obvious centralized production or distribution (*7*).

Previous reports highlighted that patients with lung injury associated with e-cigarette use have used both THC- and nicotine-containing products (*1,3,8,9*). The additional information presented here regarding the range and diversity of brands used by patients, acquisition patterns, and frequency of use helps to formulate hypotheses about the possible etiology of this outbreak. In particular, the high level of use of prefilled THC cartridges, used in a range of different devices, suggests that the cartridges might play an important role.

The findings in this report are subject to at least four limitations. First, interviews were not available for one third of patients; this nonresponse rate might introduce selection bias, although the demographics of the 86 interviewed patients were similar to those of all 127 patients. Second, because information was self-reported, there is the possibility that social desirability bias might affect reporting, particularly of illicit products; nonmedical THC use is currently illegal in both Illinois and Wisconsin. In this analysis, some patients did not disclose THC-containing product use to clinicians until late in their hospital admission or until a urinary THC screen was performed. Third, the time between urinary toxicology testing and last reported use of an e-cigarette product was not consistent and might explain the three negative results in patients who reported using THC-containing products. Finally, these data are largely drawn from patients living in the northeastern region of Illinois and southeastern region of Wisconsin, and therefore might not be generalizable to other states; however, the age and gender distribution of patients is consistent with nationwide trends (*2,3*).

The findings document that many, but not all, patients with lung injury associated with use of an e-cigarette product reported using THC-containing products. Similar findings have been noted in the national data, which include some of the data presented here (*2*). These data also reveal a predominant use of prefilled THC cartridges sold through informal and unregulated markets, although the origin of these products further back in the production and distribution chain is unknown. In addition, these data do not elucidate whether the causative exposure is THC itself or a substance associated with prefilled THC cartridges, such as a cutting agent or adulterant. Ascertaining the importance of these products in contributing to the current outbreak will require data from multiple states and analysis at the national level.

Given the number and diversity of products reported overall and by individual patients, as well as the high frequency of patients using both THC- and nicotine-containing products, the epidemiologic investigation could benefit from additional information, including product testing and traceback of e-cigarette products to identify the ultimate source of the outbreak. The Illinois Department of Public Health and the Wisconsin Department of Health Services are collaborating with CDC on a large nationwide public health response and with the Food and Drug Administration to coordinate laboratory testing of products associated with this outbreak. While this investigation is ongoing, CDC recommends that persons consider refraining from using e-cigarette, or vaping, products, particularly those containing THC.

Acknowledgments

Staff members and leadership of the Illinois Department of Public Health and Wisconsin Department of Health Services; local health departments in Illinois and Wisconsin; CDC 2019 Lung Injury Response Group; all interviewed patients.

Corresponding author: Isaac Ghinai, Isaac.Ghinai@Illinois.gov, 217-782-2016.

[1]Illinois Department of Public Health; [2]Epidemic Intelligence Service, CDC; [3]Wisconsin Department of Health Services; [4]Division of State and Local Readiness, Center for Preparedness and Response, CDC; [5]Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, CDC; [6]National Center for Environmental Health, CDC; [7]Emory University School of Medicine, Atlanta, Georgia.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

References

1. Layden JE, Ghinai I, Pray I, et al. Pulmonary illness related to e-cigarette use in Illinois and Wisconsin—preliminary report. New Engl J Med 2019. Epub September 6, 2019. https://www.nejm.org/doi/full/10.1056/NEJMoa1911614
2. Perrine CG, Pickens CM, Boehmer TK, et al. Characteristics of a multistate outbreak of lung injury associated with e-cigarette use or vaping—United States, 2019. MMWR Morb Mortal Wkly Rep 2019;68(39).
3. Schier JG, Meiman JG, Layden J, et al.; CDC 2019 Lung Injury Response Group. Severe pulmonary disease associated with electronic-cigarette-product use—interim guidance. MMWR Morb Mortal Wkly Rep 2019;68:787–90. https://doi.org/10.15585/mmwr.mm6836e2
4. Spindle T, Cone E, Schlienz N, et al. Urinary excretion profile of 11-nor-9-carboxy δ9-tetrahydrocannabinol (THCCOOH) following smoked and vaporized cannabis administration in infrequent cannabis users. Journal of Analytical Toxicology, 2019;43:233–58. https://doi.org/10.1093/jat/bky104
5. Johansson E, Halldin M. Urinary excretion half-life of δ tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. Journal of Analytical Toxicology, 1989;13:218–223. https://doi.org/10.1093/jat/13.4.218
6. Kirkham C, Dastin J. Explainer: one possible culprit in vaping lung illnesses–"dank vapes." Washington, DC: Reuters; 2019. https://www.reuters.com/article/us-health-vaping-industry-explainer/explainer-one-possible-culprit-in-vaping-lung-illnesses-dank-vapes-idUSKCN1VY2ET
7. US Department of Health and Human Services. Surgeon General's advisory on e-cigarette use among youth. Washington, DC: US Department of Health and Human Services, CDC; 2018. https://www.cdc.gov/tobacco/basic_information/e-cigarettes/surgeon-general-advisory/index.html
8. Davidson K, Brancato A, Heetderks P, et al. Outbreak of electronic-cigarette-associated acute lipoid pneumonia—North Carolina, July–August 2019. MMWR Morb Mortal Wkly Rep 2019;68:784–6. https://doi.org/10.15585/mmwr.mm6836e1
9. Maddock S, Cirulis M, Callahan A, et al. Pulmonary lipid-laden macrophages and vaping. New Engl J Med 2019. Epub September 6, 2019. https://www.nejm.org/doi/full/10/1056/NEJMc1912038

QuickStats

FROM THE NATIONAL CENTER FOR HEALTH STATISTICS

Percentage of Adults Aged 18–24 Years Who Currently Smoke Cigarettes* or Who Currently Use Electronic Cigarettes,† by Year — National Health Interview Survey, United States, 2014–2018§



* Defined as having smoked 100 cigarettes in their lifetime and currently smoking cigarettes every day or some days.
† Defined as having ever used an electronic cigarette, even one time, and currently using electronic cigarettes every day or some days.
§ Estimates are based on household interviews of a sample of the civilian, noninstitutionalized U.S. population and are derived from the National Health Interview Survey Sample Adult component. Questions on electronic cigarettes were asked of all Sample Adult respondents, regardless of cigarette-smoking status. The percentage of adults aged 18–24 years who both currently smoked cigarettes and currently used electronic cigarettes decreased from 3.3% in 2014 to 1.7% in 2018.

From 2014 to 2018, the percentage of adults aged 18–24 years who currently smoked cigarettes decreased from 16.7% to 7.8%. The percentage of adults in this age group who currently used electronic cigarettes increased from 5.1% to 7.6%.

Source: National Health Interview Survey, 2014–2018 data. https://www.cdc.gov/nchs/nhis.htm.

Reported by: Jane Williford; Benjamin Zablotsky, PhD, bzablotsky@cdc.gov, 301-458-4621; Carla Zelaya, PhD.

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, visit *MMWR* at *https://www.cdc.gov/mmwr/index.html*.

Readers who have difficulty accessing this PDF file may access the HTML file at *https://www.cdc.gov/mmwr/index2019.html*. Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Executive Editor, *MMWR* Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30329-4027 or to mmwrq@cdc.gov.

ISSN: 0149-2195 (Print)